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goal of the work described in this thesis was to determine whether the interaction between NEMO and
IKKalpha was required for non-canonical NF-kappaB signaling. We used a reconstitution approach in
knockout cells to show that IKKalpha, independent of its association with NEMO, is sufficient to control the
non-canonical NF-kappaB pathway. Thus we provide biochemical evidence to support the tenet that
IKKalpha alone regulates non-canonical NF-kappaB signaling. Importantly, while pursuing these results we
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of basal non-canonical NF-kappaB activity. These studies reveal that the previous model depicting a NEMO-
independent non-canonical NF-kappaB signaling cascade is incomplete. We show that an intact and
catalytically competent classical IKK complex constrains basal NIK accumulation. This novel mechanism of
non-canonical NF-kappaB regulation requires classical NF-kappaB transcription driven by the prototypic NF-
kappaB family member p65. Thus classical NF-kappaB activity is essential to maintain the quiescent state of
the non-canonical NF-kappaB signaling pathway. Upon activation, the duration of non-canonical signaling is
controlled by a recently described negative feedback mechanism that promotes NIK turnover. We used a
combination of translation and proteasome inhibitors to show that turnover of active NIK is proteasome-
dependent. Furthermore, we utilized a Smac mimetic compound to show that degradation of active NIK does
not require cellular inhibitor of apoptosis (cIAP)1/2, which distinguishes this feedback mechanism from the
cIAP1/2-dependent mechanism of basal NIK turnover. Collectively, these studies advance our understanding
of a recently described mechanism of non-canonical NF-kappaB down-regulation and reveal a novel interplay
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ABSTRACT 
 
MECHANISMS OF NON-CANONICAL NF-κB REGULATION 
Carolyn M. Gray 
Michael J. May, Ph.D. 
NF-κB is activated through two signaling cascades: the classical and non-canonical pathways, 
which are distinguished based on the Inhibitor of κB Kinase (IKK) components required to 
activate each pathway. Whereas classical NF-κB requires NF-κB Essential Modulator (NEMO) 
and IKKβ, non-canonical NF-κB requires IKKα and upstream stabilization of NF-κB Inducing 
Kinase (NIK), but not NEMO. However, we have previously shown that IKKα contains a functional 
NEMO binding domain and associates with NEMO and IKKβ as part of the heterotrimeric IKK 
complex. The overarching goal of the work described in this thesis was to determine whether the 
interaction between NEMO and IKKα was required for non-canonical NF-κB signaling. We used a 
reconstitution approach in knockout cells to show that IKKα, independent of its association with 
NEMO, is sufficient to control the non-canonical NF-κB pathway. Thus we provide biochemical 
evidence to support the tenet that IKKα alone regulates non-canonical NF-κB signaling. 
Importantly, while pursuing these results we made the surprising finding that NEMO, and 
furthermore, IKKβ, play a compulsory role in the constraint of basal non-canonical NF-κB activity. 
These studies reveal that the previous model depicting a NEMO-independent non-canonical NF-
κB signaling cascade is incomplete. We show that an intact and catalytically competent classical 
IKK complex constrains basal NIK accumulation. This novel mechanism of non-canonical NF-κB 
regulation requires classical NF-κB transcription driven by the prototypic NF-κB family member 
p65. Thus classical NF-κB activity is essential to maintain the quiescent state of the non-
canonical NF-κB signaling pathway. Upon activation, the duration of non-canonical signaling is 
controlled by a recently described negative feedback mechanism that promotes NIK turnover. We 
used a combination of translation and proteasome inhibitors to show that turnover of active NIK is 
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proteasome-dependent. Furthermore, we utilized a Smac mimetic compound to show that 
degradation of active NIK does not require cellular inhibitor of apoptosis (cIAP)1/2, which 
distinguishes this feedback mechanism from the cIAP1/2-dependent mechanism of basal NIK 
turnover. Collectively, these studies advance our understanding of a recently described 
mechanism of non-canonical NF-κB down-regulation and reveal a novel interplay between 
classical and non-canonical NF-κB activity, which revises the current model of non-canonical NF-
κB signaling.  
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CHAPTER 1. INTRODUCTION 
Activation of Nuclear Factor kappa B (NF-κB) [See Table 1 for common abbreviations] is 
essential for the development and maintenance of lymphocyte populations and to mount effective 
immune responses (Claudio, Brown et al. 2006; Hayden and Ghosh 2011). NF-κB is most often 
activated by extracellular stimuli such as pro-inflammatory cytokines but can also be activated by 
intrinsic signals of cellular stress (Hayden and Ghosh 2008). NF-κB signaling leads to changes in 
gene expression that are required for normal physiological processes such as cellular survival 
and differentiation, inflammation, and innate and adaptive immunity (Fig. 1). An important phase 
of NF-κB signal transduction is the down regulation of active signaling, and unconstrained NF-κB 
activity is associated with cancer and chronic inflammatory pathogenesis (Dejardin, Droin et al. 
2002; Braunersreuther and Mach 2006; Dejardin 2006; Acharyya, Villalta et al. 2007; Volger, 
Fledderus et al. 2007; Kim, Kang et al. 2008). Thus since its discovery nearly thirty years ago, 
intense effort has been made to understand the molecular mechanisms involved in NF-κB 
activation and regulation. Furthermore, modulation of the NF-κB signaling pathway has become 
an attractive target for the development of drugs designed to treat cancer and inflammatory 
diseases. 
There are two modes of NF-κB signaling, the classical and non-canonical pathways, 
which will be discussed in detail below. Each of these pathways is activated by a distinct set of 
receptors and drives the expression of unique gene programs. This dissertation focuses on 
regulatory mechanisms of the non-canonical NF-κB signaling pathway, as dysregulated non-
canonical NF-κB has been implicated in a growing number of diseases including multiple 
myeloma, Hodgkin lymphoma, pancreatic cancer, ovarian cancer, and rheumatoid arthritis 
(Annunziata, Davis et al. 2007; Keats, Fonseca et al. 2007; Jin, Zhou et al. 2009; Nishina, 
Yamaguchi et al. 2009; Wharry, Haines et al. 2009; Ranuncolo, Pittaluga et al. 2012; Noort, van 
Zoest et al. 2014). The studies presented here have unveiled a critical layer of cross talk between 
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Figure 1. Inducible NF-κB signal transduction. Diverse cellular signals activate NF-κB. NF-κB 
signaling promotes the expression of genes involved in cellular survival, inflammation, immune 
regulation, and other physiological responses.  
Inflammatory or antigenic 
insult 
NF-!B 
activation 
Pro-survival, pro-inflammatory, 
and immunoregulatory 
 gene expression 
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the classical and non-canonical NF-κB pathways. This previously unappreciated interplay will be 
important to consider in disease states affecting classical NF-κB (Orange and Geha 2003) and 
the development of novel therapeutics aimed at selectively targeting NF-κB signaling pathways.   
1.1. NF-κB signal transduction 
NF-κB is a family of transcription factors activated by a wide range of stimuli to drive the 
expression of numerous genes, including those involved in inflammation, cellular survival and 
proliferation, and lymphoid organogenesis (Claudio, Brown et al. 2006; Hayden and Ghosh 2011). 
NF-κB is ubiquitously expressed, but activation may be cell-type specific due to limited receptor 
expression. The NF-κB family contains five members: RelA (or p65), RelB, c-Rel, p50/p105 (or 
NF-κB1), and p52/p100 (or NF-κB2), which homo- and hetero-dimerize through their shared N-
terminal Rel homology domains (RHD) to control inducible gene expression (Hayden and Ghosh 
2008). p65, c-Rel, and RelB contain a C-terminal transactivation domain (TAD) through which 
they recruit transcriptional coactivators. Because they lack the TAD, p50 and p52 must bind to 
p65, c-Rel, or RelB to drive target gene transcription. Homodimers of p50 or p52 can thus only 
act as transcriptional repressors (Smale 2012).  
Under resting conditions, NF-κB proteins are inactive due to their cytoplasmic 
localization. NF-κB proteins are sequestered in the cytoplasm through their association with an 
inhibitor of κB (IκB) protein. There are three classical IκBs: IκBα, IκBβ, IκBe, and three atypical 
IκBs: IκBz, Bcl3, and IκBns (Hinz, Arslan et al. 2012). Additionally, the precursor proteins p105 
and p100 contain IκB-like regions that function to retain the unprocessed protein and associated 
NF-κB dimers in the cytoplasm (Savinova, Hoffmann et al. 2009). The proteasomal processing of 
p105 and p100 ceases at a glycine rich region, liberating the active transcription factors p50 and 
p52, respectively (Kanarek and Ben-Neriah 2012). Constitutive p105 processing to p50 is signal-
independent but signal-induced activation leads to the complete degradation of p105 and 
  
 
4 
enhanced NF-κB activity (Heissmeyer, Krappmann et al. 2001; Kanarek and Ben-Neriah 2012). 
Conversely, receptor ligation is necessary for the induced processing of p100 to p52 to activate 
NF-κB (Xiao, Harhaj et al. 2001; Xiao, Fong et al. 2004).  
In the simplest activation scheme, the stimulation-induced phosphorylation of the 
prototypical inhibitor IκBα promotes K48-linked polyubiquitylation of IκBα by the Skp1-Cul1-F-box 
(SCF) E3 ubiquitin ligase complex containing β-TrCP (hereafter referred to as β-TrCP) (Kanarek 
and Ben-Neriah 2012). Ubiquitylated IκBα is degraded via the 26S proteasome, and loss of IκBα 
reveals a nuclear localization sequence on p50/p65, thus permitting the nuclear translocation of 
the transcription factor pair. In the nucleus, NF-κB binds conserved κB sequences (5’ 
GGGRNWYYC 3’ where N, any base; R, purine; W, adenine or thymine; and Y, pyrimidine) in the 
promoters of genes involved in inflammation, proliferation, and cell survival (Hayden and Ghosh 
2008; Hayden and Ghosh 2011). Promoter occupancy may be further regulated by accessibility 
and cofactor engagement, leading to context-specific gene signatures for particular transcription 
factor pairs (Smale 2012).  
1.2. The IKK complex 
A watershed discovery in NF-κB biology was the identification of the kinase that 
phosphorylates IκB. The Inhibitor of κB Kinase, or IKK, was isolated by multiple groups using 
various molecular and biochemical techniques and was shown to have in vitro kinase activity 
against IκBα after stimulation with the pro-inflammatory cytokines Tumor Necrosis Factor (TNF) 
and Interleukin-1 (IL-1) (DiDonato, Hayakawa et al. 1997; Mercurio, Zhu et al. 1997; Regnier, 
Song et al. 1997; Woronicz, Gao et al. 1997; Zandi, Rothwarf et al. 1997; Rothwarf, Zandi et al. 
1998). IKK is a heterotrimeric complex comprised of two catalytic subunits IKKα (or IKK1) and 
IKKβ (or IKK2), and a third non-catalytic regulatory subunit NF-κB Essential Modulator (NEMO, or 
IKKγ) (Fig. 2).  IKKα and IKKβ are 85 kDa and 87 kDa, respectively, and share more than 50% 
sequence homology (Mercurio, Zhu et al. 1997; Woronicz, Gao et al. 1997; Zandi, Rothwarf et al. 
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1997). NEMO is a 45 kDa protein with numerous splice variants (Rothwarf, Zandi et al. 1998; 
Yamaoka, Courtois et al. 1998). IKKα and IKKβ associate with NEMO through a conserved six-
amino acid sequence (LDWSWL) in their C termini (May, D'Acquisto et al. 2000; May, Marienfeld 
et al. 2002). The catalytic IKKs associate stoichiometrically with NEMO in a 1:1:2 ratio (Rothwarf, 
Zandi et al. 1998) and NEMO may oligomerize further, as the IKK complex has a final molecular 
weight of 600-900 kDa (DiDonato, Hayakawa et al. 1997; Woronicz, Gao et al. 1997; Rothwarf, 
Zandi et al. 1998).  
Distinct receptor-proximal signaling events converge on the IKK complex, and activation 
of this complex is the precipitating event in NF-κB signal transduction (Hinz and Scheidereit 
2014). Importantly, in vivo deletion of each IKK component has delineated two pathways to NF-
κB activation, named classical (or canonical) and non-canonical (or alternative) NF-κB 
(Senftleben, Cao et al. 2001). These transduction cascades are activated through separate cell 
surface receptors and each controls the expression of a distinct panel of genes. The classical and 
non-canonical NF-κB pathways are discussed in detail in the next two sections. 
1.3. Classical NF-κB signaling   
Signaling through a multitude of receptors has been shown to activate classical NF-κB, 
including innate and adaptive immune receptors and cytokine receptors. Through diverse 
biochemical mechanisms, receptor-proximal signaling events converge to activate the IKK 
complex. Once active, the IKK complex phosphorylates the quintessential inhibitor IκBα on Ser-
32 and Ser-36 (DiDonato, Mercurio et al. 1996); IκBβ and IκBε are also classical NF-κB inhibitors 
that are phosphorylated by activated IKK. β-TrCP catalyzes the formation of K48-linked ubiquitin 
chains on phosphorylated IκBα, which is thus targeted for degradation via the 26S proteasome 
(Kanarek and Ben-Neriah 2012). IκBα degradation releases p50/p65 complexes for nuclear 
translocation and target gene transcription (Fig. 3). While p50/p65 is the prototype, other NF-κB 
dimers are also sequestered by IκB and are thus activated by classical signaling (Smale 2012). 
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Figure 2. The IKK complex. (A) Domain structure of the IKK proteins. Highlighted are the NEMO 
binding domains (NBD) of IKKα and IKKβ, which are required for their association with the 
regulatory subunit NEMO. (KD, kinase domain; ULD, ubiquitin-like domain; SDD, 
scaffold/dimerization domain; H, α-helix; C, coil; LZ, leucine zipper; ZF, zinc finger). (Adapted 
from Hinz and Scheidereit, EMBO 2013) (B) Schematic representation of the heterotrimeric IKK 
complex. IKKα (purple oval) and IKKβ (blue oval) associate with NEMO (peach ovals) in a 1:1:2 
ratio. 
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Because the classical signaling pathway only requires IκB degradation to release NF-κB 
dimers, activation is rapid, occurring within minutes of receptor ligation (Hayden and Ghosh 
2008). Classical NF-κB-driven genes include those encoding pro-survival and pro-proliferative 
proteins (cyclin-D1, Bcl-xL, c-FLIP, IAPs), cell adhesion molecules (VCAM, ICAM, E-selectin), 
inflammatory cytokines (TNF, IL-1, IL-6), lymphocyte activation molecules (IL-2, B7, MHC), anti-
microbial products (Defensins, COX-2), and complement proteins (Hayden and Ghosh 2011). 
Classical NF-κB activity also drives the transcription of important regulatory molecules to dampen 
the immune response. These negative regulators of NF-κB include the de-ubiquitinating enzyme 
(DUB) A20, and the inhibitory proteins IκBα and p100 (Dejardin, Droin et al. 2002; Ruland 2011). 
Biochemical analyses of individual IKK proteins have revealed a central role for IKKβ and 
NEMO in classical NF-κB signal transduction. IKKβ isolated from TNF or IL-1 stimulated HeLa 
(Zandi, Rothwarf et al. 1997) or 293 (Woronicz, Gao et al. 1997) cells can phosphorylate IκBα 
and IκBβ in vitro. Mutations in either the activation loop (S177A, S181A) or catalytic domain 
(K44M) of IKKβ block TNF-induced IκBα phosphorylation, p65 nuclear localization, and 
transcriptional activity measured by a luciferase reporter in HeLa cells (Mercurio, Zhu et al. 1997). 
A similar inactivating mutation (K44A) of IKKβ was found to block TNF or IL-1 –induced luciferase 
reporter activity in 293 cells (Woronicz, Gao et al. 1997). Moreover, a mutant rat fibroblast cell 
line (5R) and murine pre-B cell line (1.3E2) that were defective in TNF, IL-1, or 
Lipopolysaccharide (LPS) –induced IκBα or IκBβ degradation and luciferase reporter activity 
could be rescued by complementation with a cDNA encoding NEMO (Yamaoka, Courtois et al. 
1998). Finally, NEMO suppression by antisense oligonucleotides in 293 cells blocked TNF-
induced IκBα degradation and decreased DNA binding of radiolabeled κB probes measured by 
Electrophoretic Mobility Shift Assay (EMSA) (Rothwarf, Zandi et al. 1998). Together these 
seminal studies have lead to the model that NEMO and the catalytic activity of IKKβ are 
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absolutely required to phosphorylate IκB downstream of classical NF-κB stimuli (Fig. 3).  
Mice deficient in NEMO, IKKβ, or p65 die between embryonic day 10 and 15 due to 
massive hemorrhaging of the liver (Beg, Sha et al. 1995; Li, Van Antwerp et al. 1999; Li, Chu et 
al. 1999; Tanaka, Fuentes et al. 1999; Rudolph, Yeh et al. 2000). Lethality of each of these 
knockouts can be rescued by crossing them onto the TNF receptor (TNFR) null background, 
suggesting that TNF-induced hepatocyte apoptosis is the cause of death in animals that lack 
classical IKK signaling components (Gerondakis, Grumont et al. 2006). Subsequent studies have 
shown that IKKβ- and NEMO-mediated classical NF-κB signaling through p65 is absolutely 
required for pro-survival transcriptional programs downstream of the TNFR (Hayden and Ghosh 
2008), providing in vivo evidence to support the central role for NEMO and IKKβ in classical NF-
κB activation. 
Mice lacking IKKα survive until birth, but die shortly thereafter due to severe defects in 
epidermal keratinocyte differentiation affecting limb development (Hu, Baud et al. 1999; Li, Lu et 
al. 1999; Takeda, Takeuchi et al. 1999). Interestingly, this epidermal role for IKKα does not 
require IKK activity or NF-κB activation (Hu, Baud et al. 2001). Though not exclusively required 
for IκBα degradation induced by most stimuli (Solt, Madge et al. 2007), IKKα is still part of the 
heterotrimeric IKK complex that regulates classical pathway activation (Fig. 2) (Hu, Baud et al. 
1999; Li, Van Antwerp et al. 1999; Takeda, Takeuchi et al. 1999; Rudolph, Yeh et al. 2000; Muller 
and Siebenlist 2003; Solt, Madge et al. 2009). Furthermore, IKKα plays a nuclear role in Histone-
H3 phosphorylation, which is critical for cytokine-induced gene expression (Anest, Hanson et al. 
2003; Yamamoto, Verma et al. 2003). The unique phenotype of IKKα-deficient animals in 
conjunction with developmental defects in other mouse models revealed a second NF-κB signal 
transduction pathway, termed non-canonical NF-κB. 
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Figure 3. Classical NF-κB signaling. Ligation of pro-inflammatory cytokine receptors leads to 
IKK activation. IKKβ (blue oval) phosphorylates (P) IκBα (pink oval), which is degraded via the 
proteasome (gray cylinder). IκBα degradation permits the nuclear translocation of the prototypic 
p50/p65 NF-κB heterodimer (yellow and blue ovals).  
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1.4. Non-canonical NF-κB signaling  
 A collection of genetic evidence led to the discovery of the non-canonical NF-κB 
pathway. The naturally occurring alymphoplasia (aly) mutation in the gene encoding NF-κB 
Inducing Kinase (NIK, Map3k14) interferes with lymph node and Peyer’s Patch development in 
mice (Shinkura, Kitada et al. 1999; Yamada, Mitani et al. 2000). This phenotype is similar to 
animals lacking p100, Lymphotoxin (LT)β, or the LTβ receptor (LTβR) (Koni, Sacca et al. 1997; 
Caamano, Rizzo et al. 1998; Franzoso, Carlson et al. 1998; Futterer, Mink et al. 1998; Rennert, 
James et al. 1998). The immunodeficiency in these animals is largely due to defects in B cell 
development (Franzoso, Carlson et al. 1998; Yamada, Mitani et al. 2000; Senftleben, Cao et al. 
2001). Moreover, splenocytes isolated from aly/aly mice cannot be induced to process p100 ex 
vivo (Xiao, Harhaj et al. 2001; Claudio, Brown et al. 2002). NIK was discovered as a 
serine/threonine kinase that was activated downstream of the LTβR and was required for the 
phosphorylation and activation of IKKα (Malinin, Boldin et al. 1997; Matsushima, Kaisho et al. 
2001). It was later shown to induce the regulated processing of p100 via IKKα (Xiao, Fong et al. 
2004). Finally, bone marrow (BM) chimeras using BM from animals with an activation loop mutant 
version of IKKα (S176A, S180A) recapitulated the immunological defects in aly/aly mice: B cells 
developed but did not mature, and over-expression of NIK did not induce p100 processing in 
donor-derived lymphocytes that lacked functional IKKα (Senftleben, Cao et al. 2001). Thus non-
canonical NF-κB signaling requires NIK and the subsequent activation of IKKα to phosphorylate 
p100, which is then ubiquitylated and processed to p52. Together with RelB, p52 translocates to 
the nucleus. p52/RelB  drives the transcription of a panel of genes whose products are involved in 
lymphoid organization and lymphocyte development, including the homeostatic chemokines 
CXCL12, CXCL13, CCL19, CCL21, and B cell activating factor (BAFF) (Fig. 4) (Dejardin, Droin et 
al. 2002; Bonizzi, Bebien et al. 2004).   
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In addition to the LTβR, other members of the TNFR superfamily can activate the non-
canonical NF-κB pathway including CD40, receptor activator of NF-κB (RANK), TNF-related 
weak inducer of apoptosis (TWEAK) receptor, or Fn14, and B cell activating factor receptor 
(BAFF-R) (Sun 2012). Signaling through BAFF-R is required for B cell development and 
maintenance (Hayden and Ghosh 2011). Early work showed that BAFF-R signaling induced p100 
processing in splenic B cells, which was required for their maturation beyond the transitional 
stage in the spleen (Claudio, Brown et al. 2002). Unlike the rapid degradation of IκBα observed 
after classical NF-κB activation, which occurs within minutes of stimulation (Hayden and Ghosh 
2008), p100 processing does not occur until 4-24 hours after receptor ligation (Claudio, Brown et 
al. 2002). Moreover, p100 processing is blocked by the translational inhibitor cycloheximide 
(CHX), indicating that protein synthesis is required for non-canonical NF-κB activation (Claudio, 
Brown et al. 2002; Muller and Siebenlist 2003; Liang, Zhang et al. 2006).  
Unlike classical NF-κB, non-canonical signaling does not require NEMO and IKKβ, as 
p100 processing can be induced in NEMO-deficient pre-B cell lines (Claudio, Brown et al. 2002) 
and Murine Embryonic Fibroblasts (MEFs) lacking either NEMO or IKKβ (Senftleben, Cao et al. 
2001; Dejardin, Droin et al. 2002; Saitoh, Nakano et al. 2002; Muller and Siebenlist 2003). 
Instead IKKα is the critical IKK component required for p100 phosphorylation and non-canonical 
NF-κB activity mediated by p52/RelB (Senftleben, Cao et al. 2001; Dejardin, Droin et al. 2002; 
Muller and Siebenlist 2003). Collectively, these genetic studies have led to a model for non-
canonical NF-κB signaling whereby upon receptor ligation, NIK activates IKKα to phosphorylate 
p100 and promote its proteasomal processing to p52 (Fig. 4). In this scheme, IKKα is often 
depicted as a cytoplasmic homodimer, however this “IKKα-alone” complex has yet to be 
supported by definitive biochemical evidence (Hayden and Ghosh 2008; Razani and Cheng 2010; 
Sun 2012). 
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Figure 4. Non-canonical NF-κB signaling. Ligation of the LTβR, CD40, or BAFF-R promotes 
NIK stabilization (dark purple oval). NIK phosphorylates (P) IKKα (purple oval), which in turn 
phosphorylates the IκB region of the NF-κB precursor protein p100 (green oval). Phosphorylated 
p100 is ubiquitylated and partially processed by the proteasome to liberate p52/RelB (blue oval) 
NF-κB dimers.    
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1.5. NIK Regulation 
The delayed kinetics of induced p100 processing and its dependence on de novo protein 
synthesis (Claudio, Brown et al. 2002; Liang, Zhang et al. 2006) coupled with the observation that 
exogenously expressed NIK is sufficient to induce p100 processing (Xiao, Harhaj et al. 2001) led 
to the key discovery that non-canonical NF-κB signaling required NIK stabilization upstream of 
IKKα activation (Liao, Zhang et al. 2004). Structural analysis of the active site has shown that NIK 
is a constitutively active kinase (Liu, Sudom et al. 2012); thus NIK protein levels are tightly 
controlled to maintain the latent state of non-canonical NF-κB.  
In resting cells NIK is constitutively degraded through the coordinated activity of a 
complex comprised of TNFR Associated Factor (TRAF)3, TRAF2, cellular Inhibitor of Apoptosis 
(cIAP)1, and cIAP2 (Liao, Zhang et al. 2004; Vallabhapurapu, Matsuzawa et al. 2008; Zarnegar, 
Wang et al. 2008). In this model, TRAF3 associates directly with NIK, and TRAF2 associates with 
the cIAPs. TRAF2 and TRAF3 interact, which promotes NIK ubiquitylation by the cIAPs (Fig. 5A). 
Ubiquitin-conjugated NIK is constitutively degraded by the 26S proteasome in a resting cell 
(Vallabhapurapu, Matsuzawa et al. 2008; Zarnegar, Wang et al. 2008). Receptor ligation releases 
the negative regulation of the TRAF:cIAP complex on NIK, although whether this occurs by cIAP-
mediated TRAF3 degradation or by competitive displacement of NIK by the ligated receptor is 
unclear and may be cell type or receptor-specific (Liao, Zhang et al. 2004; Vallabhapurapu, 
Matsuzawa et al. 2008; Sanjo, Zajonc et al. 2010). Nevertheless, once NIK is freed from the basal 
degradation complex, NIK protein amounts increase (Fig. 5B). Because NIK is a constitutively 
active kinase (Liu, Sudom et al. 2012), protein stabilization controls NIK activity. NIK 
phosphorylates IKKα on Ser-178 (Ling, Cao et al. 1998), which activates the kinase that in turn 
phosphorylates p100, triggering its partial processing to p52 and activation of the non-canonical 
NF-κB pathway (Fig. 5B).  
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Figure 5. NIK regulation. (A) In resting cells, newly synthesized NIK (pale purple oval) 
associates with the TRAF3:TRAF2:cIAP complex. cIAP1/2 constitutively ubiquitylate NIK (black 
diamonds), leading to its proteasomal degradation. Thus NIK protein is undetectable in 
unstimulated cells and is depicted as a purple shadow. (B) Upon receptor ligation, the TRAF:cIAP 
complex localizes to the receptor, releasing NIK from its negative regulation. NIK protein 
stabilizes (dark purple oval), activating the non-canonical signaling pathway. Active IKKα 
phosphorylates (P) p100 and also feeds back to phosphorylate NIK, leading to the destabilization 
of NIK and down-regulation of non-canonical NF-κB activity. The dashed arrow indicates NIK 
turnover, but it has not been determined whether this occurs via the proteasome. 
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More recently, a negative feedback loop has been described in the non-canonical NF-κB 
pathway (Razani, Zarnegar et al. 2010). In this model active IKKα phosphorylates p100 to induce 
non-canonical signaling but also feeds back to phosphorylate active NIK (Fig. 5B). Though the 
molecular details remain unclear, this phosphorylation event leads to NIK destabilization and has 
been suggested to promote the down-regulation of non-canonical NF-κB activity (Razani, 
Zarnegar et al. 2010). Furthermore, defects in NIK turnover have been shown to promote kidney 
nephropathy (Jin, Xiao et al. 2012) and gut associated lymphoid hyperplasia (Conze, Zhao et al. 
2010; Hu, Brittain et al. 2013) in mice. Collectively, this evidence underlies the crucial role NIK 
regulation plays in the proper balance of non-canonical NF-κB activity.  
1.6. Non-canonical NF-κB signaling in human disease  
Due to its well-documented role in cell survival and proliferation, perturbations in classical 
NF-κB signaling have been associated with inflammatory pathogenesis and cancer (Staudt 2010; 
DiDonato, Mercurio et al. 2012; Lim, Yang et al. 2012). However, strong evidence has 
accumulated to implicate the non-canonical NF-κB pathway in certain lymphoid malignancies and 
chronic inflammatory diseases (Razani, Reichardt et al. 2011). 
Genetic abnormalities have been shown to promote NIK stabilization and non-canonical 
NF-κB activation in human multiple myeloma, diffuse large B cell lymphoma (DLBCL), and 
mucosal associated lymphoid tissue (MALT) lymphoma (Annunziata, Davis et al. 2007; Keats, 
Fonseca et al. 2007; Compagno, Lim et al. 2009; Demchenko, Glebov et al. 2010; Pham, Fu et 
al. 2011). Diverse mutations associated with disease have been found both in proteins that 
promote basal NIK degradation and in NIK itself. Furthermore, unconstrained signaling through 
BAFF-R has been shown to activate the non-canonical signaling pathway to drive B cell growth 
and survival in DLBCL (Pham, Fu et al. 2011). Patient samples from Hodgkin lymphoma exhibit 
constitutive NIK stabilization and RelB transcriptional activity (Ranuncolo, Pittaluga et al. 2012). In 
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addition to lymphoid malignancies, aberrant NIK activity has been identified in Pancreatic 
(Nishina, Yamaguchi et al. 2009; Wharry, Haines et al. 2009) and Ovarian cancers (Uno, Saitoh 
et al. 2014). 
Aberrant non-canonical NF-κB signaling has also been described in chronic inflammatory 
and autoimmune diseases.  Our group has shown non-canonical NF-κB activation in human 
endothelium in response to LTβR ligation (Madge, Kluger et al. 2008). Non-canonical NF-κB 
inducing stimuli, including LTαβ , LIGHT (TNFSF14), and CD40L are expressed in atherosclerotic 
lesions (Volger, Fledderus et al. 2007; Kim, Kang et al. 2008; Grabner, Lotzer et al. 2009). 
Human plaque endothelial cells exhibit nuclear p100/p52 (Rossi, Marziliano et al. 2004; Volger, 
Fledderus et al. 2007), and non-canonical regulated genes, including those expressed in 
endothelial cells, are expressed in chronic inflammatory lesions (Reape, Rayner et al. 1999; 
Braunersreuther, Mach et al. 2007; Damas, Smith et al. 2007). The non-canonical NF-κB gene 
target CXCL13 is expressed in lymphoid aggregates of patients with Sjogren’s syndrome 
(Salomonsson, Larsson et al. 2002). Finally, NIK is highly expressed in synovial tissue from 
patients with rheumatoid arthritis and is thought to drive tertiary lymphoid structure formation in 
this chronic inflammatory disease (Noort, van Zoest et al. 2014). These diverse pathological roles 
for NIK in human disease underpin the importance of elucidating the biochemical mechanisms 
underlying non-canonical NF-κB activation and down-regulation, as they may ultimately reveal 
novel therapeutic targets.  
1.7. Goals and Hypotheses 
 Mounting evidence implicates aberrant non-canonical NF-κB signaling in disease 
progression. Understanding the biochemical and molecular requirements for precise non-
canonical NF-κB regulation will reveal critical insight for the design of novel therapeutics 
selectively targeting this pathway. Therefore the overarching goal of this thesis is to dissect the 
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biochemical and molecular mechanisms governing non-canonical NF-κB activation and down-
regulation.  
 Our lab has a longstanding interest in understanding the composition and functional 
regulation of the IKK complex (May, D'Acquisto et al. 2000; May, Marienfeld et al. 2002; Solt, 
Madge et al. 2007; Solt, Madge et al. 2009). We have identified the residues through which IKKβ 
and IKKα associate with NEMO to form the heterotrimeric IKK complex (May, D'Acquisto et al. 
2000; May, Marienfeld et al. 2002), and we described a cell permeable NEMO Binding Domain 
(NBD) peptide spanning this region that potently blocks signal-induced classical NF-κB activity 
(May, D'Acquisto et al. 2000). Moreover, this peptide can disrupt pre-formed IKK complexes, 
suggesting that it competes with both IKKα and IKKβ to bind NEMO (May, D'Acquisto et al. 
2000). Genetic studies in cells lacking individual IKK components indicate that IKKβ is the 
exclusive kinase regulated by NEMO for classical NF-κB signaling and suggest that IKKα is 
redundant in this pathway (Hayden and Ghosh 2008). However, we have shown that IKKα 
contains a functional NEMO-binding domain (NBD) (Fig. 2), through which the association 
between IKKα and NEMO is critical for IL-1 mediated classical NF-κB activity (Solt, Madge et al. 
2007; Solt, Madge et al. 2009). Therefore the paradigm based on the original genetic studies 
delineating two pathways to NF-κB activation may be incomplete. 
 The model for non-canonical NF-κB signaling indicates that IKKα involved in non-
canonical signaling as a cytoplasmic homodimer (Fig. 4). However, we currently lack any 
biochemical evidence to support this “IKKα-alone” scheme. An additional void in our 
understanding of non-canonical NF-κB activation is how NIK specifically targets IKKα for 
phosphorylation. As we have previously shown that IKKα contains a functional NBD that directs 
its assembly into the heterotrimeric complex and promotes classical NF-κB activation by IL-1 
(Solt, Madge et al. 2007; Solt, Madge et al. 2009), we surmise that the IKKα involved in non-
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canonical NF-κB activation is also associated with NEMO. Specifically, we hypothesized that the 
association between NEMO and IKKα is necessary to regulate non-canonical NF-κB signaling. 
 To ask whether the NEMO:IKKα association was important for the induction of non-
canonical NF-κB, we created a cell line in which IKKα lacked the NBD and thus cannot associate 
with NEMO and IKKβ as part of the heterotrimeric IKK complex. Non-canonical NF-κB activation 
occurs with normal kinetics in these cells, and we definitively show that the NEMO:IKKα 
association is dispensable for IKKα-mediated turnover of active NIK (Chapter 3). These studies 
therefore support the current model that NEMO is not required for inducible non-canonical NF-κB 
signaling. However in parallel experiments using NEMO-deficient cells, we identified a role for 
NEMO in the negative regulation of non-canonical NF-κB signaling via NIK protein amounts 
(Chapter 3). We show that in addition to NEMO, IKKβ is required for the basal constraint of NIK 
(Chapter 4). This unexpected regulatory mechanism requires a signal-competent IKK complex 
and transcriptional activity mediated by the prototypical NF-κB family member p65 to maintain the 
quiescent state of the non-canonical NF-κB pathway (Chapter 4).  Importantly, our studies 
provide compelling evidence that this novel interplay between the classical and non-canonical 
NF-κB pathways occurs in patients with hypomorphic mutations in the NEMO protein (Chapter 4) 
(Gray, Remouchamps et al. 2014). 
 Our overarching goal is to understand molecular mechanisms of non-canonical NF-κB 
regulation. A negative feedback loop to control the duration of non-canonical signaling was 
recently described that implicates IKKα in the negative turnover of active NIK (Fig. 5B) (Razani, 
Zarnegar et al. 2010), which we show does not require the association of IKKα with NEMO 
(Chapter 3). However, this newly proposed model is poorly defined and it remains to be 
determined how phosphorylated NIK is degraded and which other cellular factors facilitate this 
process. We hypothesized that like basal NIK, active NIK is degraded via cIAP1/2-dependent 
proteasomal degradation. In chapter 5, we show that active NIK turnover is indeed proteasome-
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dependent but does not require cIAP1/2. These findings therefore delineate the molecular 
requirements for basal NIK degradation from those required for the turnover of stimulation-
induced NIK. 
This thesis describes novel regulatory mechanisms of basal and active non-canonical 
NF-κB signaling. The studies presented here expand our understanding of a new mechanism that 
controls the duration of non-canonical NF-κB activity as well as revise our former understanding 
of basal NIK regulation and the interplay between the classical and non-canonical NF-κB 
signaling pathways. Ultimately, cross talk between classical and non-canonical NF-κB signaling 
will be critical to consider when manipulating these pathways to treat NF-κB-associated 
pathologies. 
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CHAPTER 2. MATERIALS AND METHODS  
2.1. Cell Lines and Culture  
3T3-NIH Mouse Embryonic Fibroblasts and Hela cells were purchased from ATCC 
(Manassas, VA). The 3T8 Jurkat T cell line has been described elsewhere (He and Ting 2002) 
and had been previously mutagenized to create the NEMOKO cell line 8321 (He and Ting 2002). 
These 8321 cells were reconstituted with full-length NEMO to create 8321WT cells in earlier 
studies (Hanson, Monaco-Shawver et al. 2008). TRAF3KO, p65KO, and p65WT MEFs were kindly 
provided by Emmanuel Dejardin (University of Liège, Belgium).  
All fibroblasts and Plat-E cells were cultured in Dulbecco’s modified Eagle’s medium 
(Invitrogen) supplemented with 10% fetal bovine serum (Atlanta Biologicals), 2mM L-glutamine, 
penicillin (50 units/mL) and streptomycin (50 units/mL). Jurkat T cells were cultured in RPMI 
medium (Invitrogen) supplemented with 10% fetal bovine serum (Invitrogen), 2mM L-glutamine, 
penicillin (50 units/mL) and streptomycin (50 units/mL).  Cells were passaged with 0.25% Trypsin 
(Invitrogen). Unless otherwise noted, cells were stimulated with TNF (10ng/mL), LIGHT 
(100ng/mL), anti-LTβR (300ng/mL), or Smac mimetic (1µg/mL) when they reached 80% 
confluence.   
2.2. Human Umbilical Vein Endothelial Cell (HUVEC) Isolation 
HUVECs were isolated from discarded tissue in accordance with a protocol approved by 
the University of Pennsylvania Institutional Review Board. Following collagenase digestion (1 
mg/ml in PBS) from the canulated umbilical vein, endothelial cells were serially cultured on 
gelatin-coated tissue culture plastic in Vasculife VEGF-MV complete media supplemented with 
penicillin (50 units/mL) and streptomycin (50 units/mL). All experiments were performed on cells 
between passages 2-3. 
 
  
 
21 
2.3. Patient Samples 
Patient peripheral blood mononuclear cells (PBMCs) were obtained with parental consent 
and with approval by the Children’s Hospital Committee on Clinical Investigation, Children’s 
Hospital Boston, as described elsewhere (Orange, Jain et al. 2004). Clinical presentations and 
immunological findings from these patients were previously reported (Orange, Jain et al. 2004; 
Hanson, Monaco-Shawver et al. 2008). 
2.4. Antibodies and Reagents  
Antibodies against NIK (4994S), Histone-H3 (9715S), phospho-IKKα/β (2697S) and 
mouse-p100/p52 (4882S) were purchased from Cell Signaling Technology (Beverly, MA). Anti-
human p100/p52 (05-361) was from Millipore (Billerica, MA). Anti-NEMO antibody (K0159-3) was 
purchased from MBL International (Woburn, MA). Anti-IKKα (IMG-136A) and anti-IKKβ (IMG-
129A) antibodies were purchased from Imgenex (San Diego, CA). Monoclonal anti-cIAP1 
antibody (mAb 1E1-10) was purchased from Enzo Life Sciences (Farmingdale, NY). Anti-NEMO 
antibody was purchased from MBL International (Woburn, MA). Antibodies against NEMO (sc-
8330), IκBα (sc-371), IKKα (sc-7218 ), TRAF3 (sc-947), TRAF2 (sc-876), cIAP-2 (D19), and 
TBK1 (sc-52957) were purchased from Santa Cruz Biotechnology (Dallas, TX). Anti-cIAP2 
(AF8171) and pan-cIAP1/2 (Mab 3400) antibodies were purchased from R&D Systems 
(Minneapolis, MN). Anti-α-Tubulin (T5168) was from Sigma-Aldrich (St. Louis, MO). Horseradish 
Peroxidase-conjugated secondary antibodies and normal rabbit serum were from Jackson 
Immuno Research (West Grove, PA). Fluorescently labeled secondary antibodies were 
purchased from LI-COR Biosciences (Lincoln, NE). Agonistic antibody against the LTβR (clone 
5G11) was purchased from Abcam (Cambridge, MA).  
Cycloheximide was purchased from Calbiochem (239764). Protein λ-phosphatase (NEB 
P0753S) was purchased from New England Biosciences (Ipswich, MA). Recombinant human 
LIGHT (TNFSF14) and TNF-α were purchased from R&D Systems (Minneapolis, MN). Protein-G 
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agarose beads, and MG132 (10µM) were from Sigma-Aldrich (St. Louis, MO). Fugene-6 (E-
269A) and the dual luciferase reporter assay kit (E1980) were purchased from Promega 
(Madison, WI). Fast-digest restriction enzymes were purchased from Thermo Fisher Scientific 
(Pittsburgh, PA). Bortezomib was a generous gift from Katherine A. High, M.D. (The Perelman 
School of Medicine at The University of Pennsylvania). The active Smac mimetic GT13072 and 
the inactive Smac mimetic GT13199 were generously provided by TetraLogic Pharmaceuticals 
(Malvern, PA). 
2.5. Generation of Stable Cell Lines 
All cloning procedures were performed using the Pfu Turbo PCR procedure as previously 
described (Solt, Madge et al. 2009).  Briefly, cDNAs encoding full length (WT) and ΔNBD (1-734 
lacking the NEMO-binding domain) IKKα were subcloned into the EcoR1 and Xho1 restriction 
sites of the Super MigR1 vector (kindly provided by Warren Pear, The University of 
Pennsylvania). Platinum-E cells were transfected with the appropriate vector using Fugene-6 with 
a 3:1 ratio of Fugene:DNA, according to the manufacturer’s instructions. Twenty-four and 48 
hours later, retroviral supernatants were collected and filtered through sterile cell strainers 
(40µm). If not used immediately, retrovirus was stored at -80°C. IKKαKO MEFs were transduced 
with retroviral supernatants containing 8µg/mL Polybrene. After two rounds of transduction, 
IKKαWT and IKKαΔNBD cells were FACS sorted at the Flow Cytometry and Cell Sorting Resource 
Laboratory at The University of Pennsylvania on a BD FACSVantage with DiVa option sorter 
based on GFP expression. IKKα protein expression was confirmed by immunoblot.  
Complimentary DNAs encoding full length (NEMOWT), NEMO 86-419 (NEMOΔNBD), and 
WT IKKβ were subcloned into the EcoR1 and Xba restriction sites of the Super MigR1 vector, and 
Platinum-E cells were transfected to create retroviral supernatants as described above. NEMOKO 
MEFs were retrovirally transduced and FACS sorted to create stable NEMOWT, NEMO86-419, or 
NEMOKO-IKKβ cell lines as described above.  
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Complimentary DNAs containing full-length or Kinase dead (K44M) IKKβ were ligated 
into the HindIII and Not1 restriction sites of LZRS-pBMN-lacZ retroviral vector (kindly provided by 
Dr. Garry Nolan, Stanford University, La Jolla, CA).  Pheonix cells were transfected as described 
above. Vector-containing cells were selected using Puromycin (8 μg/mL) 24 hours after 
transfection. Conditioned medium from Puromycin-resistant cells was used to transduce IKKβKO 
MEFs and create stable IKKβWT or IKKβK44M cell lines. 
2.6. Immunoblotting and Immunoprecipitation 
Cells were harvested on ice in a lysis buffer consisting of 150mM NaCl, 50mM TrisCl pH 
7.5, 1% Triton X-100, and complete protease inhibitors (Roche).  Proteins were separated by 
SDS-PAGE in Tris-Glycine running buffer (25 mM Tris, 250 mM glycine, 0.1% (w/v) SDS) and 
transferred onto PVDF membrane (Millipore) in transfer buffer (25 mM Tris, 192 mM glycine, 20% 
(v/v) methanol). Membranes were blocked in 5% non-fat milk and incubated with primary 
antibodies overnight at 4°C with gentle rocking. Membranes were washed three times in TBS-T 
(25 mM Tris–HCl, pH 8.0, 140 mM NaCl, 3 mM KCl, 0.05% Tween-20) and incubated with 
secondary antibody for one hour at room temprature. Membranes were washed three times with 
TBS-T and developed using enhanced chemiluminescence (ECL). ECL was made by mixing 
equal volumes of solution 1 and solution 2. (Solution 1: 200 µL 250 mM luminol (in DMSO), 88 µL 
90 mM p-coumaric acid (in DMSO), 2 mL 1M Tris-HCl pH 8.5, 17.7 mL dH2O. Solution 2: 12 µL 
30% H2O2 (v/v), 2 mL Tris-HCl pH 8.5, 18 mL dH2O). Unless otherwise noted, the immunoblots 
presented are one of three representative experiments. 
For immunoprecipitations, 500 µg total protein was cleared using normal rabbit serum. 
Lysates were then incubated with 1ug of indicated antibody and Protein-G agarose beads for 12 
hours at 4°C under rotary agitation. Beads were washed four times in 0.1% TNT (150 mM NaCl, 
50 mM TrisCl pH 7.5, 0.1% Triton X-100), boiled in reducing sample buffer (5x; 0.3 M TrisCl pH 
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6.8, 5% SDS, 50% Glycerol, 100 mM DTT), and samples were divided onto two SDS-PAGE gels 
for immunoblot as described above.   
2.7. Luciferase Reporter Assay 
Cells cultured in 12-well plates were transiently transfected using Fugene 6 according to 
the manufacturer’s protocol. Cells were transfected with a total of 500 ng DNA per well comprised 
of the NF-κB-dependent pBIIX-Firefly luciferase reporter construct (FF, 450 ng/well) and the 
Thymidine Kinase (TK)-dependent Renilla Luciferase reporter (RL, 50ng/well). Twenty-four hours 
after transfection, cells were treated with TNF (10 ng/mL) for five hours and lysed in 1X Passive 
Lysis Buffer (Promega) for 15 minutes at room temperature. Samples were run in quadruplicate 
using a Luminoscan 96-well automated luminometer (Thermo LabSystems, Franklin, MA), and 
FF:RL ratios were calculated using Ascent software (Thermo LabSystems). Means are from at 
least three independent experiments and P-values were calculated using a student’s two-tailed t-
test or one-way ANOVA in Prism software. 
2.8. Preparation of Nuclear and Cytosolic Extracts 
Cells were scraped into PBS at 4°C and pelleted (425 x g for 10 min). Pellets were 
resuspended and swollen for 10 min on ice in 100µl Buffer A (10 mM HEPES, pH 7.9, 10 mM 
KCl, 0.1 mM EDTA, 2 mM NaF, 2 mM β-glycerophosphate, and complete mini protease 
inhibitors) plus 0.1% Nonidet P-40 and centrifuged (3800 x g) for 1 min.  Supernatants 
(cytoplasmic fraction) were snap frozen and retained. Pelleted nuclei were washed four times with 
Buffer A plus 0.1% Nonidet P-40 before being resuspended in Buffer C (20 mM HEPES pH 7.9, 
0.4 M NaCl, 1 mM EDTA, 2 mM NaF, 2 mM β-glycerophosphate, and complete mini protease 
inhibitors) and vortexed on high at 4°C for 60 minutes. Supernatants were centrifuged (14000 
RPM) for twenty minutes at 4°C.  Nuclear lysates were either used immediately or snap frozen 
and stored at -80°C.  Lysates were immunoblotted as described above. 
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2.9. Electrophoretic Mobility Shift Assay (EMSA) 
 Single stranded complimentary oligonucleotides encompassing a consensus NF-κB site 
(upper strand, 5’-AGTTGAGGGGACTTTCCCAGGC-3’) were annealed and labeled with [γ−32P] 
ATP using T4 polynucleotide kinase (New England Biolabs, Beverly, MA). The labeled probe was 
then purified using the mini-Quick Spin columns (Roche Applied Science) according to the 
manufacturer’s protocol. Nuclear extracts were prepared as described in section 2.8. 5 µg of 
lysate supplemented with 1 µg of poly (dI:dC) (Roche Applied Science) was incubated with an 
equal volume of 2X binding buffer (40 mM Tris-HCl pH 7.9, 100 mM NaCl, 10 mM MgCl2, 2 mM 
EDTA, 10% glycerol, 0.2% NP-40, 2 mM DTT, 100 µg/ml BSA) on ice for 10 minutes. After the 
incubation, 1 µl of labeled probe was added and then incubated at room temperature for 20 
minutes. The resulting DNA:protein complexes were separated on 5% polyacrylamide non-
denaturing gels by electrophoresis. The gels were then dried and visualized by autoradiography.   
2.10. NBD peptide 
NBD peptides (NBDp) were obtained from the Howard Hughes Medical Institute 
Biopolymer-Keck Foundation Biotechnology Resource Laboratory at Yale University (New Haven, 
CT). Immediately prior to use, the peptides were dissolved in dimethyl sulfoxide (DMSO) to a 
stock concentration of 200 mM. The sequences of the WT and mutant NBD peptides (NBDp and 
mutNBDp, respectively) have been described previously (May, D'Acquisto et al. 2000). Peptides 
were used at a final concentration of 100 µM. 
2.11. mRNA isolation and Quantitative Real Time PCR analysis 
RNA was isolated using the RNase Easy Spin Kit (Qiagen) according to the 
manufacturer’s instructions. Samples were subject to on-column DNase digestion.  Semi-
quantitative amplification of target genes was performed using Power SYBR Green (Applied 
Biosystems) according to the manufacturer’s instructions. PCR products were generated in 
quadruplicate and normalized to β-actin (actb) using the ABI 7500 Real-Time PCR system. 
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Relative quantitation (RQ) was derived from the difference in cycle threshold (Ct) between the 
gene of interest and β-actin using the equation RQ = 2-ΔΔCt and analyzed using SDS v1.3 
software. PCR product specificity was confirmed by performing a dissociation curve with each 
experiment. The map3k14 QuantiTect Primer Assay was purchased from Qiagen; the actb primer 
pair (5’-ACC CAC ACT GTG CCC ATC TA-3’, 3’-ATC GGA ACC GCT CGT TGC-5’), p100 primer 
pair (5’-CAG AAA CTT CAG AGG CAG CGT-3’ and 5’-GCA AAT AAA CTT CGT CTC CAC CG-
3’) and birc3 primer pair (5’-CTG GCC AAA GCA GGC TTC TAC TAC-3’, 3’-CAC GCT ACC CTT 
TGA CTC GTT GAC-5’) were from Integrated DNA Technologies. 
2.12. Protein quantification and statistical analyses 
Western blots were quantified with background subtraction using the LI-COR Odyssey 
imaging system or ImageJ software (National Institutes of Health).  For each method the intensity 
of the band of interest was normalized to its corresponding control band (α-Tubulin, β-Actin, or 
Histone-H3). Each value was normalized back to the unstimulated (WT) control and relative 
arbitrary units are shown. Statistical analyses for at least three independent experiments were 
performed using Prism software. A student’s two-tailed t-test or one-way ANOVA with Dunnett’s 
post-test to the WT control were performed for all data sets with a significance cutoff of P < 0.05. 
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CHAPTER 3. IKK REQUIREMENTS FOR NON-CANONICAL NF-κB REGULATION 
Portions of this chapter have previously been published as: Gray CM, Remouchamps C, 
McCorkell KA, Solt LA, Dejardin E, Orange JS, and May MJ. Non-canonical NF-κB signaling is 
limited by classical IKK activity. Sci Signal. 7, ra13(2014).  
3.1. Introduction 
Diverse upstream signals converge on the IKK complex to activate NF-κB pathways. 
Analyses of NF-κB signaling in MEFs lacking individual components of the IKK complex have 
established that inducible p100 processing can occur in the absence of either NEMO or IKKβ 
(Senftleben, Cao et al. 2001; Dejardin, Droin et al. 2002; Derudder, Dejardin et al. 2003). Thus it 
has been concluded that IKKα alone is required for regulation of the non-canonical pathway and 
that the major IKK complex responsible for NIK-induced activation is an IKKα homodimer (Fig. 4). 
Despite this model, very little biochemical evidence exists to support a definitive role for an “IKKα-
alone” complex in the non-canonical NF-κB pathway. Furthermore, our previous work established 
that IKKα contains a functional NBD (Fig. 2), suggesting that NEMO may associate with IKKα 
homodimers (Solt, Madge et al. 2007; Solt, Madge et al. 2009). We therefore sought to determine 
whether the association of NEMO with IKKα played any role in regulating the non-canonical NF-
κB pathway. We hypothesized that the IKKα:NEMO association was necessary for non-canonical 
NF-κB activation and down-regulation mediated by IKKα.   
In this chapter, we utilized cell lines lacking IKKα or NEMO to determine whether the 
association between these key signaling mediators was important for p100 processing and NIK 
turnover. We show here that a mutant version of IKKα that cannot associate with NEMO is 
sufficient for non-canonical NF-κB activation and NIK turnover. Thus we provide biochemical 
evidence to support the current model that IKKα alone is required for non-canonical NF-κB 
signaling. However, parallel studies led us to the surprising finding that the classical IKK complex 
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is critical for the negative regulation of non-canonical NF-κB signaling through the basal stability 
of NIK. 
3.2. Results 
3.2.1. Association of IKKα with NEMO is dispensable for non-canonical NF-κB activation 
Upon LTβR cross-linking, IKKα is required to phosphorylate p100, leading to its 
proteasomal processing to p52 and, ultimately, non-canonical NF-κB-dependent gene expression 
(Dejardin, Droin et al. 2002). Despite its conserved NBD (May, D'Acquisto et al. 2000; Solt, 
Madge et al. 2009), genetic evidence has implicated IKKα homodimers in non-canonical NF-κB 
activity (Sun 2012). To determine whether the association of NEMO with IKKα specifically plays a 
role in the induction of non-canonical NF-κB signaling, we stably reconstituted IKKαKO MEFs with 
either MigR1 vector alone, wild-type IKKα (IKKαWT), or a version of IKKα that lacks the C-terminal 
NBD (IKKαΔNBD) (Fig. 6A) (Solt, Madge et al. 2009). IKKαΔNBD retains the ability to interact with 
IKKβ but is unable to interact with NEMO specifically (Fig. 6B). This cell line allows us to 
specifically test, at the molecular level, whether the association of NEMO and IKKα is required for 
non-canonical NF-κB signaling.  
We assessed the ability of IKKα-reconstituted cells to induce p100 processing after 
stimulation with LIGHT. Stimulation of WT MEFs with LIGHT led to transient stabilization of NIK 
and p100 processing to p52 (Fig. 7, lanes 1-7), indicating non-canonical NF-κB activity. Basal 
NIK was detected in un-stimulated MigR1-transduced IKKαKO cells and was further stabilized in 
response to LIGHT (Fig. 7, lanes 8-14). This observation is consistent with a role for IKKα in the 
destabilization of active NIK and has been described previously (Razani, Zarnegar et al. 2010). 
Notably, reconstitution of IKKαKO cells with either IKKαWT or IKKαΔNBD restored undetectable 
basal levels of NIK. In addition, stimulation of both IKKαWT and IKKαΔNBD MEFs with LIGHT 
induced NIK stabilization and p100 processing with kinetics similar to untransduced WT cells (Fig.  
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Figure 6. Generation of IKKαWT and IKKαΔNBD MEF cell lines. (A) Schematic representation of 
the domain structure of IKKα. The NEMO-binding domain (NBD) is absent in IKKαΔNBD. (B) 
Depiction of IKK complexes in IKKαKO MEFs reconstituted with IKKαWT or IKKαΔNBD. In addition to 
these classical complexes, we previously established that IKKαWT and IKKαΔNBD homodimers are 
also present in these respective reconstituted MEF lines (Solt et al. 2009). (C) Left: WT and 
IKKαKO MEFs retrovirally transduced with MigR1 or with MigR1 encoding either IKKαWT or 
IKKαΔNBD were lysed, and whole-cell lysates were analyzed by Western blotting with antibodies 
against the indicated proteins. Right: Immunoprecipitations (IP) were performed with anti-IKKα 
and anti-NEMO antibodies, as indicated, to show IKK complex formation. Blots are representative 
of four independent experiments.  
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Figure 7. The association between NEMO and IKKα  is dispensable for inducible p100 
processing. WT and IKKα-deficient (IKKαKO) MEFs retrovirally transduced with either MigR1 
alone or MigR1 expressing IKKαWT or IKKαΔNBD were incubated with LIGHT for the indicated 
times. Cell lysates were then analyzed by Western blotting with antibodies against the indicated 
proteins.  
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7, lanes 15-28). Thus we conclude that binding to NEMO is not required for IKKα to regulate 
p100 processing in response to LIGHT. This dissection of the NEMO:IKKα association provides 
biochemical evidence to support the current model of NEMO-independent activation of the non-
canonical NF-κB pathway by IKKα. 
3.2.2. IKKαΔNBD is sufficient to promote NIK turnover 
We next questioned whether the association of IKKα with NEMO was required for the 
IKKα-dependent turnover of active NIK. This negative feedback loop was described based on the 
observation that LTβR stimulation permits NIK protein accumulation in WT MEFs, but protein 
amounts decrease after sustained activation, whereas NIK protein levels continually increase in 
stimulated IKKα-deficient cells (Razani, Zarnegar et al. 2010). Mutational analyses established 
that IKKα phosphorylates NIK on three serine residues to promote NIK destabilization, but the 
investigators never actually visualized the rate of endogenous NIK turnover to confirm this model 
(Razani, Zarnegar et al. 2010). Assessing active NIK turnover is complicated because NIK is 
continually synthesized in a resting cell; protein levels are constrained due to the E3 ubiquitin 
ligase activity of the basal degradation complex and thus NIK is undetectable until an activating 
stimulus is encountered. When a cell is activated through the LTβR, for example, the basal 
regulatory machinery is disrupted and NIK protein accumulates. However, this pool of active NIK 
continues to be filled by newly synthesized protein (Fig. 8). Thus we established a CHX chase 
strategy to inhibit new protein synthesis, permitting us to detect active NIK turnover and 
determine whether the interaction between IKKα and NEMO was required for this process. 
To visualize active NIK turnover we incubated MEFs with LIGHT for four hours to induce 
NIK accumulation, then incubated cells with CHX for up to one hour to prevent new protein 
synthesis. Supporting the model of IKKα-dependent feedback regulation (Razani, Zarnegar et al. 
2010), LIGHT-induced NIK was rapidly lost in WT MEFs whereas NIK remained detectable after  
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Figure 8. The pool of active NIK is continually filled with newly translated protein. Upon 
receptor ligation, the TRAF:cIAP complex localizes to the receptor, releasing NIK from its 
negative regulation. NIK protein stabilizes (dark purple oval), activating the non-canonical 
signaling pathway. Newly synthesized NIK continues to accumulate. Active IKKα phosphorylates 
(P) p100 and also feeds back to phosphorylate NIK, leading to the destabilization of NIK. The 
dashed arrow indicates NIK turnover, but it has not been determined whether this occurs via the 
proteasome. 
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Figure 9. An association between NEMO and IKKα  is dispensable for active NIK turnover. 
WT, IKKαKO, and IKKαKO MEFs transduced with the indicated constructs were incubated for 4 
hours with LIGHT and then were treated either with cycloheximide (CHX) for the indicated times 
or with ethanol for 60 min as a vehicle control (V). Lysates were then analyzed by Western 
blotting with antibodies against the indicated proteins. Western blots are representative of four 
independent experiments. 
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sixty minutes of CHX incubation IKKα-deficient cells (Fig. 9). Furthermore, both IKKαWT and 
IKKαΔNBD restored NIK turnover in IKKαKO cells, demonstrating that the ability of active IKKα to 
feedback and destabilize LIGHT-induced NIK (Razani, Zarnegar et al. 2010) is independent of its 
association with NEMO (Fig. 9). Collectively, these results establish that the association with 
NEMO is dispensable for both the activation and down-regulation of non-canonical NF-κB by 
IKKα.  
3.2.3. Elevated p100 processing in the absence of NEMO  
 We performed parallel experiments in NEMO-deficient (NEMOKO) MEFs to discern 
whether the NEMO:IKKα association might have a role in non-canonical NF-κB activity. 
Unexpectedly, as we pursued these studies, we observed elevated basal p52 amounts in 
unstimulated NEMOKO MEFs compared with resting WT cells (Fig. 10, A and B). LIGHT or an 
agonistic anti-LTβR antibody (α-LTβR) could further enhance p100 processing in NEMOKO MEFs 
(Fig. 10A, lane 6). However, in some experiments basal p52 levels were already maximal in 
NEMO-deficient cells and could not be increased by activating ligands (Fig. 11, A and B). In light 
of the prevailing model that NEMO plays no role in non-canonical NF-κB activity (Fig. 4), basal 
p100 processing in the absence of NEMO is surprising, as this result suggests that NEMO is 
actually required to suppress non-canonical NF-κB activity. 
To further examine the activation status of non-canonical NF-κB signaling in the absence 
of NEMO, we isolated cytoplasmic and nuclear fractions from resting and anti-LTβR stimulated 
MEFs. Fractions were immunoblotted with antibodies against the non-canonical NF-κB proteins 
p52 and RelB to assess whether elevated p52 in NEMO-deficient cells had localized to the 
nucleus, where it might be transcriptionally active. As shown in Figure 12A, p52 was absent in 
nuclear samples from unstimulated WT or IKKαKO MEFs, and as expected, anti-LTβR induced the  
nuclear translocation of p52 in WT but not IKKαKO cells. Consistent with elevated basal p100  
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Figure 10. NEMO constrains basal p100 processing in MEFs. (A) WT, IKKαKO, and NEMOKO 
MEFs were either untreated (-) or were stimulated with LIGHT for 12 hours (+). Cell lysates were 
then analyzed by Western blotting with antibodies against the indicated proteins. (B) Basal 
extents of p100 processing in unstimulated WT, IKKαKO, and NEMOKO MEFs graphed to present 
the mean ratios of the abundances of p52 and p100 proteins normalized to the abundance of 
tubulin.  Data are means ± SEM from five independent experiments. ***P < 0.001 by one-way 
ANOVA and Dunnett’s post-test. 
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Figure 11. Inducible p100 processing in NEMO-deficient MEFs. (A) WT, IKKαKO, and 
NEMOKO MEFs were either left untreated (-) or incubated with anti-LTβR antibody for 12 hours 
(+). Whole-cell lysates were then prepared and analyzed by Western blotting with antibodies 
against the indicated proteins. (B) Quantification of the extent of p100 processing in the indicated 
cells before (-) or after (+) treatment with anti-LTβR antibody. Data are graphed to present the 
mean ratios of the abundances of p52 and p100 proteins normalized to the abundance of tubulin 
protein. Data are means ± SEM from three independent experiments. *P < 0.05, **P < 0.001 by 
one-way ANOVA and Dunnett’s post-test. 
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Figure 12. Elevated nuclear p52/RelB amounts in NEMO-deficient MEFs. (A) WT, IKKαKO, 
and NEMOKO MEFs were either left untreated (-) or were incubated with anti-LTβR antibody (α-
LTβR) for 12 hours (+). Cytoplasmic and nuclear extracts were then prepared and analyzed by 
Western blotting with antibodies against the indicated proteins. Western blots are representative 
of three independent experiments. (B) Quantification of the relative fluorescence of nuclear 
fractions similar to those shown in (A). Data are mean fluorescence values ± SEM of p52 (white 
bars) and RelB (black bars) relative to that of Histone H3 from three independent experiments.    
P  > 0.05 by one-way ANOVA.   
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processing in cells lacking NEMO (Fig. 10), nuclear p52 was present in unstimulated NEMOKO 
MEFs and increased following LTβR ligation (Fig. 12A, lanes 11 and 12). Furthermore, nuclear 
RelB was present in resting NEMOKO MEFs compared with unstimulated WT and IKKαKO cells, 
and RelB nuclear translocation was markedly enhanced by anti-LTβR (Fig. 12A, compare lane 1 
with lanes 11 and 12). These data reveal that the basal amounts of nuclear p52 and RelB in 
NEMOKO MEFs are similar to the LTβR-induced levels in WT cells  (Fig. 12B). Consistent with 
elevated nuclear p52 and RelB, transcription of the non-canonical NF-κB gene target Cxcl12 
(Dejardin, Droin et al. 2002; Madge, Kluger et al. 2008; Madge and May 2010) was significantly 
increased in unstimulated NEMOKO MEFs compared to resting WT cells (Fig. 13). Overall these 
data indicate that the non-canonical NF-κB signaling pathway is basally active in NEMO-deficient 
MEFs, which challenges the prevailing model for non-canonical NF-κB regulation. 
To confirm these findings are not unique to MEFs, we assessed p100 processing in the 
NEMO-deficient Jurkat T cell line 8321. 8321 cells were identified in a mutagenesis screen of the 
parental 3T8 cell line for mutations that prevented the induction of a NF-κB-dependent reporter 
(He and Ting 2002). Immunoblotting confirmed that these cells lacked full-length NEMO (He and 
Ting 2002). As in NEMOKO MEFs (Fig. 10), p52 was elevated in unstimulated 8321 cells 
compared with the parental 3T8 line containing WT NEMO (Fig. 14). Reconstitution of 8321 cells 
with wild-type NEMO (8321WT) (He and Ting 2002) restored basal p100 processing (Fig. 14). 
Collectively, these findings establish that intact NEMO maintains the inactive state of non-
canonical NF-κB signaling in resting cells.   
3.2.4. NIK is present in cells lacking NEMO 
Non-canonical NF-κB activation requires ligand-induced NIK stabilization (Senftleben, 
Cao et al. 2001; Xiao, Harhaj et al. 2001; Dejardin, Droin et al. 2002).  Since genetic loss of 
NEMO results in elevated p100 processing and cxcl12 expression in the absence of stimulating 
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Figure 13. Basal Cxcl12 transcript amounts in unstimulated MEFs. Relative amounts of 
Cxcl12 mRNA in unstimulated WT, IKKαKO, and NEMOKO MEFs relative to that of Actb mRNA. 
Data are means ± SEM from six independent experiments. **P < 0.01 by one-way ANOVA and 
Dunnett’s post-test.  
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Figure 14. Basal p100 processing in NEMO-deficient T cells can be rescued by WT NEMO. 
Whole-cell lysates from the 3T8 and NEMO-deficient 8321 Jurkat T cell lines and from 8321 cells 
reconstituted with WT NEMO (8321WT) were analyzed by Western blotting with antibodies against 
the indicated proteins.  
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ligands (Figs. 10-14), we asked whether NIK protein amounts were also dysregulated in the 
absence of NEMO. As expected, NIK was undetected in resting WT MEFs but was stabilized by 
treatment with LIGHT (Fig. 15A, lanes 1 and 2). Consistent with the recently reported role for 
IKKα in regulating NIK turnover (Razani, Zarnegar et al. 2010), NIK was present in unstimulated 
IKKα-deficient cells, and further enhanced following LIGHT stimulation (Fig. 15A, lanes 3 and 4).  
Strikingly, NIK was present in resting NEMOKO MEFs (Fig. 15A, lane 5), and these amounts were 
either unchanged (Fig. 15A, lane 6) or minimally enhanced by LIGHT stimulation. Despite 
significantly elevated NIK protein in NEMOKO MEFs compared to WT MEFs (Fig. 15B), 
quantitative RT-PCR showed similar abundance of Map3k14 in WT, IKKαKO, and NEMOKO cells 
(Fig. 16), indicating that constitutively stabilized NIK in NEMO-deficient MEFs is not due to 
increased transcription of the gene that encodes NIK. 
We next analyzed NIK in the NEMO-mutant 8321 cells that exhibited elevated p100 
processing (Fig. 14). Basal NIK was markedly higher in 8321 cells lacking NEMO than in 
unstimulated parental 3T8 cells (Fig. 17A). Similarly, NIK was elevated in resting NEMO-deficient 
Rat5R fibroblasts compared with parental Rat1 cells (Fig. 17B). These data from separate cell 
types and different species strongly suggest that NEMO negatively regulates NIK protein levels.  
To confirm this novel function of NEMO, we reconstituted NEMOKO MEFs with WT NEMO 
(NEMOWT), and as shown in Figure 18 (A and B), basal p100 processing was limited in 
unstimulated NEMOWT MEFs. Aberrantly stabilized NIK was also ablated in unstimulated 
NEMOWT MEFs (Fig. 19). Moreover, LIGHT stimulation led to NIK stabilization in NEMOWT MEFs 
analogous to the activation of WT MEFs (Fig. 19, compare lanes 7 and 8 with lanes 1 and 2). 
Hence exogenous NEMO rescues basal NIK regulation in NEMO-deficient MEFs. 
We next questioned whether the role of NEMO in NIK protein regulation was related to its 
ability to interact with the catalytic IKKs. To address this we reconstituted NEMOKO MEFs with a 
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Figure 15. NEMO constrains the accumulation of NIK protein.  (A) WT, IKKαKO, and NEMOKO 
MEFs were either left untreated (-) or incubated with LIGHT for 12 hours (+). Cell lysates were 
then analyzed by Western blotting with antibodies against the indicated proteins. (B) 
Quantification of the abundance of NIK protein relative to that of tubulin in the experiments 
represented by the Western blot in (A). Data are means ± SEM from three independent 
experiments.  *P < 0.05 by one-way ANOVA and Dunnett’s post-test.  
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Figure 16. NEMO deficiency does not affect Map3k14 transcription. Analysis of the 
abundance of Map3k14 mRNA (which encodes NIK) relative to Actb mRNA in WT, IKKαKO, and 
NEMOKO MEFs. Data are means ± SEM from four independent experiments, P > 0.05 by one-
way ANOVA.  
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Figure 17. Elevated basal NIK in NEMO-deficient cells. (A and B) Lysates from WT and 
NEMO-deficient Jurkat cells (A) and Rat1R fibroblasts (B) were analyzed by Western blotting with 
antibodies against the indicated proteins.  
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Figure 18. The association between NEMO and IKKα /β  is required to constrain basal p100 
processing. (A) Lysates from WT or NEMOKO MEFs retrovirally transduced with MigR1 (as a 
control) or with MigR1 encoding WT NEMO or NEMO 86-419 were analyzed by Western blotting 
with antibodies against the indicated proteins. (B) Quantification of the extent of p100 processing 
to generate p52 in cell lysates from three independent experiments represented by the Western 
blot in (A). Data are graphed to present the mean ratios of the abundances of p52 and p100 
proteins normalized to the amount of β-actin protein. Data are means ± SEM from three 
independent experiments. *P < 0.01 by one-way ANOVA and Dunnett’s post-test.   
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Figure 19. The association between NEMO and IKKα /β  is required to constrain NIK 
amounts. WT, NEMOKO, and NEMOKO MEFs retrovirally transduced with either control MigR1 
vector or with MigR1 encoding WT NEMO or a truncated mutant NEMO (86-419) were either 
untreated (-) or incubated with LIGHT for 12 hours (+) before cell lysates were analyzed by 
Western blotting with antibodies against the indicated proteins. Western blots are representative 
of four independent experiments.  
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Figure 20. Classical NF-κB signaling in NEMO-reconstituted MEFs. (A) Schematic 
representation of the domain structure of NEMO showing the α-helical domain absent in NEMO86-
419 (H1). (C, coil; LZ, leucine zipper; ZF, zinc finger (B) Depiction of the classical IKK complexes 
in NEMOKO MEFs reconstituted with NEMOWT or NEMO86-419. (C) WT, NEMOKO, and NEMOKO 
MEFs retrovirally transduced with MigR or with MigR encoding either NEMOWT or NEMO86-419 
were lysed, and immunoprecipitations (IP) were performed with anti-IKKα or anti-NEMO 
antibodies, as indicated. Samples before immunoprecipitation (Pre-IP) and immunoprecipitated 
samples were then analyzed by Western blotting with antibodies against the indicated proteins. 
Blots are representative of three independent experiments. (D) The indicated cells were 
transfected with the pBIIx-κB firefly luciferase (FFL) and the TK renilla luciferase (RL) vectors. 
Twenty-four hours later, cells were either left untreated (Control; white bars) or were stimulated 
with TNF-α for five hours (black bars). NF-κB transcriptional activity was determined as the 
fluorescence ratio of firefly:renilla luciferase (RLU, relative luciferase units). Data are means ± SD 
of four replicates from one of three independent experiments. 
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NEMO truncation mutant unable to bind either IKKα or IKKβ (NEMO86-419) and thereby unable to 
rescue classical NF-κB activation (Fig. 20). Notably, NIK remained detectable in unstimulated 
NEMO86-419 MEFs, similar to NEMO-deficient cells (Fig. 19, lane 9). Further, basal p100 
processing remained elevated in NEMO86-419 MEFs (Fig. 18, A and B). These data indicate that 
NEMO must associate with either IKKα or IKKβ to properly constrain basal NIK.   
3.2.5. The classical IKK complex is required for basal NIK regulation 
As dissociation of NEMO from IKKα alone does not affect basal p100 processing or NIK 
stability (Figs. 7 and 9), the findings in Figures 18 and 19 led us to ask whether IKKβ might be 
involved in the NEMO-dependent negative regulation of NIK. To address this we examined non-
canonical NF-κB signaling in resting IKKβ-deficient (IKKβKO) MEFs, and similar to NEMOKO cells, 
basal p52 was elevated (Fig. 21). Consistent with previous reports (Dejardin, Droin et al. 2002), 
p100 processing was further enhanced by LIGHT stimulation in IKKβKO MEFs, confirming that 
inducible non-canonical NF-κB signaling was intact in the absence of IKKβ (Fig. 21).   
To determine whether basal p100 processing in IKKβ-deficient cells was caused by a 
similar mechanism observed in NEMO-deficient cells, we investigated NIK protein amounts in 
IKKβKO MEFs. Consistent with our observations in NEMOKO cells, NIK was significantly elevated 
in resting IKKβKO MEFs, and treatment with LIGHT or anti-LTβR led to additional NIK stabilization 
(Fig. 22A, lanes 10-12 and 22B). Examination of a second independently generated IKKβKO MEF 
line confirmed these findings (Fig. 22C). Constitutive IKKα phosphorylation was detected in 
IKKβKO cells prior to stimulation (Fig. 22A, lane 10), further indicating that the non-canonical NF-
κB pathway is basally active in these cells.   
We hypothesized that reconstitution of IKKβKO MEFs with WT IKKβ could restore NIK 
regulation. As expected, stable transduction of IKKβKO MEFs with WT IKKβ (IKKβWT) but not a 
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Figure 21. Non-canonical NF-κB activity in IKKβKO MEFs. WT, IKKαKO, NEMOKO, and IKKβKO 
MEFs were either untreated (-) or incubated with LIGHT for 12 hours (+) before cell lysates were 
analyzed by Western blotting with antibodies against the indicated proteins.   
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Figure 22. Elevated NIK amounts in IKKβKO MEFs. (A) The indicated MEF cell lines were 
either untreated (-) or were stimulated with LIGHT (L) or anti-LTβR antibody (Ab) for 12 hours 
before cell lysates were analyzed by Western blotting with antibodies against the indicated 
proteins. Active IKK was detected with an antibody specific for phosphorylated IKKα/β (p-IKKα/β). 
(B) Quantification of NIK protein abundance in WT and IKKβKO MEFs. Data are means ± SEM 
from three independent experiments. **P < 0.01 by a student’s two-tailed t-test. (C) WT MEFs 
and two independently derived IKKβKO MEF cell lines (β1 and β2) were either left untreated (-) or 
were treated with anti-LTβR antibody for 8 hours (+). Cell lysates were then analyzed by Western 
blotting with antibodies against the indicated proteins. Blots are representative of three 
independent experiments.  
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Figure 23. IκBα  degradation in WT and IKKβ-reconstituted MEFs. (A) WT and IKKβKO MEFs 
and (B) IKKβKO MEFs reconstituted with IKKβWT or IKKβK44M were incubated with TNF-α for the 
indicated times, and IκBα degradation was detected by Western blotting analysis with antibodies 
against the indicated proteins.  Blots are representative of data from three experiments. 
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Figure 24. The catalytic activity of the IKK complex is required to constrain basal non-
canonical NF-κB activity. (A) WT, IKKβKO, and IKKβKO MEFs retrovirally transduced with LZRS 
or LZRS expressing either IKKβWT or a catalytically inactive mutant IKKβ (IKKβK44M) were either 
untreated (-) or incubated with LIGHT for 12 hours (+) before cell lysates were analyzed by 
Western blotting with antibodies against the indicated proteins. (B) Lysates from WT, IKKβKO 
MEFs, and IKKβKO MEFs reconstituted with LZRS or WT IKKβ were analyzed by Western blotting 
with antibodies against the indicated proteins. Blots are representative of three independent 
experiments.   
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catalytically inactive version of the kinase (IKKβK44M) rescued classical NF-κB signaling (Fig. 23).  
Importantly IKKβWT, but not IKKβK44M, reduced basal NIK (Fig. 24A), demonstrating that the 
catalytic activity of IIKKβ is required to properly regulate NIK. Moreover, reconstitution of IKKβ-
deficient cells with WT IKKβ reduced basal IKKα phosphorylation (Fig. 24B), indicating that 
elevated NIK is required for the robust IKKα activation seen in these cells. Collectively these 
findings establish that basal regulation of the non-canonical NF-κB pathway requires the intact 
and catalytically active classical IKK complex (Fig. 25).   
3.3. Discussion 
 In this chapter we sought to determine whether the conserved NBD in IKKα played a 
functional role in non-canonical NF-κB signaling. We took two complementary approaches to 
understand whether IKKα could promote p100 phosphorylation independent of the heterotrimeric 
IKK complex. First, we complemented IKKα-deficient MEFs with a mutant version of IKKα that is 
unable to associate with NEMO. Signal-induced p100 processing was intact in IKKα-deficient 
cells reconstituted with the mutant IKKα. Our findings therefore provide definitive biochemical 
support for the tenet that IKKα alone, independent of its association with the classical IKK 
complex, is sufficient to induce p100 processing. These data do not determine whether “IKKα-
alone” complexes exist in vivo, but rather they support the genetic model in which IKKα is 
capable of fully activating the non-canonical NF-κB pathway.  
Since the NEMO:IKKα interaction is not required for the activation of the non-canonical 
NF-κB pathway, we questioned a potential role for this association in the newly described 
negative feedback loop to terminate active signaling. Feedback inhibition of NIK requires its 
IKKα-mediated phosphorylation (Razani, Zarnegar et al. 2010). Here we describe an 
experimental strategy using LIGHT-induced NIK accumulation coupled with the translational 
inhibitor cycloheximide (CHX) to directly visualize active NIK turnover. We show that the IKKα-
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mediated turnover of endogenous NIK occurs in the absence of IKKα binding to NEMO. Thus we 
conclude that IKKα does not need to associate with NEMO to negatively regulate non-canonical 
NF-κB activity. 
In addition to complementing IKKα-deficient cells, we assessed non-canonical NF-κB 
activation in NEMO-deficient MEFs. In light of the prevailing model in which the classical IKK 
complex plays no role in the non-canonical pathway (Sun 2011), we were surprised to detect 
elevated basal p100 processing in cells lacking NEMO. In most cases p100 processing could be 
further enhanced by stimulation with LIGHT or anti-LTβR; however, in some instances p52 in 
NEMO- or IKKβ-deficient cells appeared saturated. Moreover, the ratio of p52 to p100 in 
untreated NEMOKO MEFs was similar to that in maximally stimulated WT MEFs, suggesting that 
non-canonical signaling is fully active in the absence of NEMO. Careful examination of the 
literature indicates that these findings are consistent with earlier studies in which IKKα was 
catalytically active and p100 was basally processed to p52 in unstimulated NEMO-deficient cells 
(Senftleben, Cao et al. 2001; Claudio, Brown et al. 2002; Dejardin, Droin et al. 2002; Derudder, 
Dejardin et al. 2003). However, these observations were never highlighted or addressed in the 
original papers and the notion that non-canonical NF-κB signaling is intact in the absence of 
NEMO has been the prevailing conclusion. Thus, because activating stimuli could further induce 
p100 processing in NEMO-deficient cells over elevated basal amounts, the widely accepted 
model states that non-canonical NF-κB signaling is NEMO-independent. Our data establish that 
this model is incomplete and should include a role for NEMO in basal suppression of the non-
canonical pathway (Fig. 25). 
 In seeking to determine the mechanism for enhanced basal p100 processing, we found 
NIK to be significantly elevated in resting cells lacking either NEMO or IKKβ. Consistent with 
active p100 processing, NIK detected in the absence of NEMO or IKKβ resembled NIK induced 
by stimulation of WT MEFs with LIGHT or anti-LTβR; this further corroborates that non-canonical 
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NF-κB signaling is basally active in these cells. We also found NEMO and IKKβ must interact, 
and the catalytic activity of IKKβ is required for basal NIK regulation. Hence we conclude that in 
resting cells, the intact and catalytically competent classical IKK complex maintains basal NIK 
regulation and prevents constitutive p100 processing to p52 (Fig. 25).   
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Figure 25. The non-canonical NF-κB signaling pathway is basally active in the absence of 
NEMO or IKKβ . (A) The classical IKK complex constrains NIK levels in unstimulated cells. (B) In 
the absence of NEMO or IKKβ, NIK protein levels stabilize, leading to p100 processing and 
activation of the non-canonical NF-κB pathway.  
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CHAPTER 4. CLASSICAL NF-κB SIGNALING NEGATIVELY REGULATES NON-CANONICAL 
NF-κB ACTIVITY 
Portions of this chapter were previosly published as: Gray CM, Remouchamps C, McCorkell KA, 
Solt LA, Dejardin E, Orange JS, and May MJ. Non-canonical NF-κB signaling is limited by 
classical IKK activity. Sci Signal. 7, ra13(2014).  
4.1. Introduction 
NIK is a constitutively active kinase required for non-canonical NF-κB signal transduction. 
Therefore, NIK protein levels are under stringent post-translational regulation (Fig. 4). In resting 
cells, newly synthesized NIK is rapidly degraded by a complex consisting of TRAF2, TRAF3, 
cIAP1, and cIAP2 (Liao, Zhang et al. 2004; Varfolomeev, Blankenship et al. 2007; 
Vallabhapurapu, Matsuzawa et al. 2008; Zarnegar, Wang et al. 2008), and upon receptor ligation 
(e.g. LTβR) NIK is freed from this complex and accumulates in the cytoplasm (Liao, Zhang et al. 
2004; Vallabhapurapu, Matsuzawa et al. 2008; Zarnegar, Wang et al. 2008).  Stabilized NIK 
phosphorylates IKKα, which in turn leads to p100 processing and non-canonical NF-κB 
activation. Recently, IKKα has also been shown to phosphorylate active NIK, triggering its 
degradation (Razani, Zarnegar et al. 2010). The precise phosphorylation-dependent mechanism 
of NIK turnover is unclear, but this negative feedback loop is crucial to eliminate NIK and is 
thought to down-regulate non-canonical NF-κB signaling (Fig. 5B). 
Our results in chapter 3 reveal an unprecedented role for the classical IKK complex in the 
basal constraint of non-canonical NF-κB signaling. These findings prompt reassessment of the 
mechanisms that control NIK protein stability. In this chapter, we investigate the role of the 
classical IKK complex in basal NIK stabilization and active NIK turnover. We hypothesized that 
the classical IKK complex directly phosphorylated active NIK, facilitating its turnover by IKKα. 
However, our results reveal that classical NF-κB transcriptional activity mediated by p65 is 
required for the negative regulation of basal NIK, which is a surprising interplay between the 
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classical and non-canonical NF-κB pathways. Moreover, we identify a population of patients with 
mutations in NEMO for whom this novel regulatory function may be important clinically. 
4.2. Results 
4.2.1. NEMO and NIK interact via IKKα  
 To begin to identify how the classical IKK complex may regulate NIK protein levels, we 
asked whether NEMO could associate with endogenous NIK. Because NIK is constitutively 
degraded in resting cells, we treated cells with the proteasome inhibitor MG132 for four hours to 
stabilize NIK. Immunoprecipitation (IP) using an antibody against NEMO accessed the 
heterotrimeric IKK complex consisting of IKKα and IKKβ as well as NIK (Fig. 26A). However, 
reciprocal pull-downs with an antibody raised against the C terminus of the NIK protein 
immunoprecipitated NIK itself but none of the IKKs (Fig. 26A). This may be due to antibody 
interference of NIK interactions, as IP of endogenous NIK with this antibody has also never co-
immunoprecipitated any members of the basal regulatory complex (TRAF3, TRAF2, or cIAP1, not 
shown). NIK and IKKα have been shown to interact when exogenously expressed (Lin, Mu et al. 
1998; Ling, Cao et al. 1998; Xiao, Harhaj et al. 2001) to induce p100 processing (Xiao, Harhaj et 
al. 2001). We thus performed control pull-downs with an anti-IKKα antibody to IP NIK. 
Immunoprecipitation of IKKα pulled down NIK, NEMO, and a small amount of IKKβ (Fig. 26A lane 
5).  
Because the association with NEMO is not required for IKKα to function in the non-
canonical NF-κB pathway (Figs. 7 and 9), we questioned whether NEMO pulled down NIK via an 
association with IKKα or whether NEMO associated with NIK directly. To test this, we performed 
the same biochemical analysis on lysates from IKKαKO MEFs. The NEMO:NIK association was 
lost in the absence of IKKα (Fig. 26A, lane 8), suggesting that IKKα may serve as a molecular 
bridge between NIK and NEMO.  
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Figure 26. The classical IKK complex may associate with endogenous NIK but does not 
interact with the basal degradation complex. (A) WT and IKKαKO MEFs were treated with 
MG132 (25 µM) for four hours to stabilize NIK. Cells were lysed, and immunoprecipitations (IP) 
were performed with anti-NEMO, anti-NIK, or anti-IKKα antibodies, as indicated. Samples before 
immunoprecipitation (-) and immunoprecipitated samples were then analyzed by Western blotting 
with antibodies against the indicated proteins. (B) WT and IKKαKO MEFs were either untreated (-) 
or treated with MG132 (25 µM, +) for four hours to stabilize NIK. Cells were lysed and analyzed 
as in (A). 
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To investigate whether the association with NEMO might be important for basal NIK 
turnover, we asked whether NEMO associated with TRAF3, which is required for the constitutive 
degradation of NIK in resting cells (Liao, Zhang et al. 2004; Vallabhapurapu, Matsuzawa et al. 
2008; Zarnegar, Wang et al. 2008). We therefore immunoprecipitated NEMO and immunblotted 
for endogenous NIK and TRAF3.  Despite binding NIK, we have been unable to detect an 
association between NEMO and endogenous TRAF3, even in the absence of MG132 (Fig. 26B). 
Because TRAF3 is a critical component of the basal NIK regulatory complex and NEMO does not 
associate with TRAF3, we thought this result indicated that the classical IKK complex might not 
be important for basal NIK degradation. Furthermore, because IKKα is required for the 
association of NEMO and NIK (Fig. 26A), and IKKα promotes the destabilization of active NIK, 
we hypothesized that the classical IKK complex may facilitate IKKα-mediated turnover of NIK. 
4.2.2. Classical IKK is not required for NIK phosphorylation by IKKα  
The recently described negative feedback loop leading to degradation of NIK requires 
phosphorylation by IKKα (Razani, Zarnegar et al. 2010).  This prevents prolonged non-canonical 
NF-κB signaling and can be visualized by a single unphosphorylated NIK band detected in 
IKKαKO MEFs (Fig. 15A, lanes 3 and 4). Our results from Figure 23 suggest that NEMO, which 
associates with NIK via IKKα, may pay a role in this process. As shown in Figure 27A, λ-
phosphatase treatment of LIGHT-stimulated MEFs caused NIK in WT, NEMOKO, and IKKβKO cells 
to migrate with the same electrophoretic mobility as unphosphorylated NIK in IKKαKO MEFs.  
Moreover, λ-phosphatase treatment reduced the molecular weight of stabilized NIK in TRAF3-
deficient MEFs, in which basal NIK degradation is defective (Fig. 27B) (He, Zarnegar et al. 2006).  
Contrary to our original hypothesis that the classical IKK complex facilitates IKKα-mediated NIK 
turnover, these data indicate that active NIK is properly phosphorylated by IKKα in MEFs lacking 
NEMO, IKKβ, or TRAF3, similar to WT cells. 
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Figure 27. NEMO and IKKβ  are dispensable for the IKKα-mediated phosphorylation of 
active NIK. (A) Left: The indicated cells were incubated with LIGHT for 4 hours, and then cell 
lysates were prepared and either left untreated (-) or incubated with λ-phosphatase (ptase; +) 
before being analyzed by Western blotting with antibodies against the indicated proteins. The 
asterisk indicates the band corresponding to phosphorylated NIK. Right: Loading controls to show 
the abundances of NIK, IKKα, IKKβ, and NEMO in lysates of the indicated LIGHT-stimulated cells 
before treatment with phosphatase. (B) TRAF3KO MEFs were processed and analyzed as 
described in (A).                     
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As our results suggest both IKKα and IKKβ are required for the overall regulation of NIK 
protein, we assessed NIK stability in IKKα/β double-knockout (DKO) MEFs. Consistent with these 
findings, NIK was detectable in unstimulated DKO MEFs (Fig. 28A). Similar to IKKαKO MEFs, 
there was no electrophoretic shift indicating IKKα-mediated NIK phosphorylation in DKO MEFs 
when compared to NIK in stimulated WT cells (Fig. 28B).  λ-phosphatase treatment enhanced the 
electrophoretic mobility of NIK from unstimulated NEMOKO and IKKβKO MEFs but not from DKO 
MEFs (Fig. 28B).  These data demonstrate that in cells lacking either NEMO or IKKβ, NIK is 
basally phosphorylated in an IKKα-dependent manner.   
4.2.3. Active NIK turnover is independent of the classical IKK complex  
Our accumulated findings establish that NIK is present and basally phosphorylated by 
IKKα in NEMO- or IKKβ-deficient MEFs. As NIK associates with NEMO in the presence of IKKα 
(Fig. 26), we asked whether the intact classical IKK complex is required for the IKKα-dependent 
degradation of active NIK (Razani, Zarnegar et al. 2010). Consistent with inducible activation of 
the non-canonical pathway in NEMOKO and IKKβKO cells, NIK was enhanced in these cells 
following LIGHT treatment; this active NIK was degraded in the presence of CHX with similar 
kinetics to NIK in WT MEFs (Fig. 29).  As expected, NIK remained stable with CHX treatment in 
DKO MEFs confirming that negative feedback in the absence of the intact classical IKK complex 
requires IKKα. Furthermore, activation-induced turnover is independent of the basal NIK 
regulatory complex, as active NIK in TRAF3KO cells was degraded similar to NIK in WT, NEMOKO 
and IKKβKO MEFs (Fig. 29). These data definitively show that the classical IKK complex is not 
required for IKKα-mediated turnover of activated NIK.   
We next questioned whether the basally elevated and IKKα-phosphorylated NIK present 
in resting NEMOKO and IKKβKO MEFs resulted from a general defect in protein turnover.  As 
shown in Figure 30, CHX treatment of unstimulated NEMOKO and IKKβKO MEFs led to loss of 
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Figure 28. Increased NIK abundance in IKKα /β  DKO MEFs. (A) WT and IKKα/β DKO MEFs 
were either untreated (-) or were stimulated with LIGHT (L) or anti-LTβR antibody (Ab) for 4 
hours. Cell lysates were then analyzed by Western blotting with antibodies against the indicated 
proteins. (B) Lysates from resting IKKαKO, NEMOKO, IKKβKO, and DKO MEFs were treated with λ-
phosphatase before being analyzed by Western blotting with antibodies against the indicated 
proteins. Blots are representative of three independent experiments.    
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Figure 29. The classical IKK complex does not facilitate the turnover of active NIK. WT, 
NEMOKO, IKKβKO, DKO, and TRAF3KO MEFs were incubated for 4 hours with LIGHT and then 
were either treated with cycloheximide (CHX) for the indicated times or were treated for 60 min 
with ethanol as a vehicle control (V). Cell lysates were analyzed by Western blotting with 
antibodies against the indicated proteins.  
Tubulin 
Tubulin 
CHX (min) 
Tubulin 
NIK 
Tubulin D
K
O
 
NIK 
N
E
M
O
K
O
 
IK
K
!K
O
 
NIK 
NIK 
Tubulin 
T
R
A
F
3K
O
 
1 2 3 4 5 6 7 8 
0 0 5 15 30 45 60 V 
4 hours LIGHT 
W
T
 NIK  
  
 
65 
 
basal NIK. In contrast unphosphorylated NIK in both resting IKKαKO and DKO cells was highly 
stable and remained detectable after two hours of CHX treatment (Fig. 30).  Thus we conclude 
that the classical IKK complex does not regulate IKKα-mediated NIK turnover but instead plays a 
separate, obligate role in limiting the basal pool of newly synthesized NIK. 
4.2.4. Classical NF-κB activity is required for basal NIK regulation  
 Our accumulated results suggest that classical IKK activity is required to constrain basal 
NIK and thus non-canonical NF-κB signaling. We reasoned that this could occur via one of two 
mechanisms. First, the IKK complex may phoshorylate NIK directly via IKKβ, facilitating its basal 
turnover via the TRAF3:TRAF2:cIAP1/2 complex. While NEMO associates with endogenous NIK, 
we have never identified an interaction between NEMO and TRAF3 (Fig. 26). Additionally, 
elevated NIK is basally phosphorylated in NEMOKO and IKKβKO MEFs (Fig. 27A), suggesting that 
IKKβ kinase activity does not target NIK directly. An alternative model for basal NIK constraint by 
the classical IKK complex is that a gene product of classical NF-κB signaling is required to 
regulate NIK amounts. 
To address this second possibility, we assessed non-canonical NF-κB activity in MEFs lacking 
the prototypic classical NF-κB subunit p65 (p65KO). Similar to unstimulated NEMOKO and IKKβKO 
MEFs, NIK was elevated in p65KO MEFs prior to stimulation with anti-LTβR (Fig. 31A). 
Quantitative RT-PCR in p65KO MEFs showed classical NF-κB signaling did not control Map3k14 
transcription directly (Fig. 31B). As in NEMOKO and IKKβKO MEFs (Fig. 27A), λ-phosphatase 
treatment revealed that active NIK was phosphorylated in p65KO MEFs (Fig. 31C).  Furthermore, 
low resting NIK was partially rescued by stable reconstitution of p65-deficient MEFs with a WT 
version of p65 (Fig. 31D). Collectively, these results indicate that p65-driven gene transcription is 
required for basal NIK regulation. 
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Figure 30. Basal NIK stability in the absence of NEMO or IKKβ . Unstimulated IKKαKO, 
NEMOKO, IKKβKO, and DKO MEFs were incubated with CHX for the indicated times or with 
ethanol (V) for 120 min before cell lysates were prepared and analyzed by Western blotting with 
antibodies against the indicated proteins. Western blots are representative of four independent 
experiments.   
NIK 
Tubulin 
NIK 
Tubulin 
NIK 
Tubulin 
Tubulin 
NIK 
0 5 15 30 45 60 90 120 V CHX (min) 
IK
K
!
K
O
 
N
E
M
O
K
O
 
IK
K
"K
O
 
D
K
O
 
1 2 3 4 5 6 7 8 9 
  
 
67 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 31. Classical NF-κB–dependent gene expression is required to regulate basal NIK 
abundance. (A) WT or p65KO MEFs were left unstimulated or were treated with either LIGHT (L) 
or the anti-LTβR antibody (Ab) for 4 hours. Cell lysates were then analyzed by Western blotting 
with antibodies against the indicated proteins. (B) RNA from WT or p65KO MEFs was isolated and 
analyzed by quantitative RT-PCR to determine the abundance of Map3k14 mRNA in comparison 
to that of actb mRNA. Data are means ± SEM from three independent experiments. P > 0.05 by 
student’s two-tailed t-test. (C) WT and p65KO MEFs were stimulated with LIGHT for 4 hours. 
Whole-cell extracts were then left untreated or were treated with λ-phosphatase (ptase) and 
analyzed by Western blotting with antibodies against the indicated proteins. The asterisk 
indicates the band corresponding to phosphorylated NIK. (D) p65KO MEFs were transduced with 
empty pBABE vector or the pBABE vector encoding WT p65. Cell lysates were then analyzed by 
Western blotting with antibodies against the indicated proteins.  
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Since classical NF-κB activity does not affect Map3k14 transcription directly (Figs. 16 and 
31B), we sought to determine whether any of the known modulators of basal NIK expression 
were deregulated in p65KO MEFs. The molecular components regulating basal NIK form the 
TRAF2:TRAF3:cIAP1:cIAP2 E3 ubiquitin ligase complex (Sun 2012).  We found TRAF2, TRAF3, 
cIAP1, and cIAP2 amounts to be similar or elevated in p65KO MEFs compared to WT (Fig. 32A), 
consistent with a potential role for non-canonical NF-κB signaling in TRAF3 expression (Sasaki, 
Calado et al. 2008).  As cIAP2 (Birc3) is a classical NF-κB gene target (Chu, McKinsey et al. 
1997), we assessed Birc3 transcripts in p65KO MEFs and found similar amounts in p65KO and WT 
MEFs (Fig. 32B). In addition, Birc3 transcription was intact in NEMOKO MEFs, suggesting that 
disruption of the classical IKK complex does not affect basal Birc3 transcription. We therefore 
conclude that cIAP2 is not the molecular target of classical NF-κB signaling that controls basal 
NIK regulation. cIAP1, TRAF2 and TRAF3 protein amounts were similar if not elevated among 
the cell lines we studied (Fig. 33), and TRAF3 stability was unaffected by loss of classical NF-κB 
activity (Fig. 34).  Notably, over-expressed NIK was able to associate with endogenous TRAF3, 
TRAF2, and cIAP1 in the absence of NEMO or p65 (Fig. 35). Together these data suggest that 
aberrant NIK detected in the absence of NEMO, IKKβ, or p65 is not due to alteration of the 
currently known NIK regulatory machinery.   
4.2.5. Classical NF-κB transcriptional activity rescues basal NIK amounts 
 Loss of p65 in MEFs permits basal NIK stabilization and p100 processing, similar to loss 
of the upstream signaling components NEMO or IKKβ, indicating that classical NF-κB 
transcriptional activity is required to actively suppress basal non-canonical NF-κB signaling. We 
therefore hypothesized that enforced classical NF-κB activity could rescue aberrant non-
canonical NF-κB signaling in NEMOKO MEFs. To test this we transduced NEMOKO MEFs with 
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Figure 32. p65 does not regulate the expression of the basal NIK regulatory complex. (A) 
Whole-cell extracts from WT or p65KO MEFs were analyzed by Western blotting with antibodies 
against the indicated proteins. (B) RNA was isolated from unstimulated WT, p65KO, and NEMOKO 
MEFs for quantitative RT-PCR analysis of Birc3 expression. Data are means ± SEM of Birc3 
mRNA abundance relative to that of actb mRNA from three independent experiments. P > 0.05 
by one-way ANOVA.  
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Figure 33. Basal NIK regulatory complex expression in IKK-deficient MEFs. Lysates from 
WT, IKKαKO, NEMOKO, and IKKβKO MEFs were analyzed by Western blotting with antibodies 
against the indicated proteins.  
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Figure 34. TRAF3 stability in IKK-deficient MEFs. Unstimulated IKKαKO, NEMOKO, and IKKβKO 
MEFs were incubated with cycloheximide (CHX) for the indicated times or with ethanol as a 
vehicle control (V) for 120 min. Cell lysates were then analyzed by Western blotting with anti-
TRAF3 and anti-tubulin antibodies. Blots are representative of four independent experiments.  
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Figure 35. FLAG-NIK associates with the endogenous basal NIK regulatory complex in 
NEMOKO and p65KO  MEFs. WT, NEMOKO, and p65KO MEFs were transfected with pFLAG-
CMV2-NIK. Top: FLAG-tagged NIK was immunoprecipitated (IP) with FLAG (M2) beads, and co-
immunoprecipitation of NIK with endogenous TRAF3, TRAF2, and cIAP1 was determined by 
Western blotting analysis. Bottom: Western blotting analysis of the abundances of the indicated 
proteins in whole-cell lysates (WCL) of samples before they were subjected to 
immunoprecipitation. Blots are representative of three experiments.   
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MigR1 empty vector or MigR1 containing WT IKKβ to create stable cell lines over-expressing 
IKKβ. Over-expression of WT IKKβ alone was sufficient to drive classical NF-κB transcriptional 
activity, even in the absence of NEMO (Fig. 36A). Furthermore we observed reduced NIK 
amounts and lower basal p100 processing in NEMOKO MEFs that over-expressed WT IKKβ 
compared to controls (Fig. 36B), which further confirms that classical NF-κB transcriptional 
activity is required to actively suppress basal NIK and thus non-canonical NF-κB signaling.     
4.2.5. Hyperactive non-canonical NF-κB activity in NEMO-ID  
Non-canonical NF-κB has recently been found to control immunoglobulin class-switch 
recombination to the IgA isotype in activated B cells (Jin, Xiao et al. 2012).  Prolonged NIK 
stability enhances non-canonical NF-κB signaling, and mice with elevated NIK display high serum 
titers of IgA (Jin, Xiao et al. 2012). Notably, a subset of patients with inherited mutations in NEMO 
exhibits hyper-IgA (Orange, Jain et al. 2004). These patients have a complex immunodeficiency 
termed NEMO-immunodeficiency (NEMO-ID) due to defects in classical NF-κB signaling; 
however, the mechanisms underlying the unusual clinical presentation of hyper-IgA have not 
been explained by the lack of classical NF-κB activity (Orange, Jain et al. 2004). Our studies in 
MEFs reveal a novel layer of cross talk between classical NF-κB signaling and basal NIK 
regulation; we therefore hypothesized that the defects in class-switch observed in NEMO-ID 
patients was due to basal activity of non-canonical NF-κB.  
To assess the status of the non-canonical NF-κB pathway in samples from NEMO-ID 
patients previously shown to have impaired classical NF-κB activation and elevated serum IgA 
(Orange, Jain et al. 2004; Hanson, Monaco-Shawver et al. 2008), we compared p100 processing 
in unstimulated peripheral blood mononuclear cells (PBMCs) from two patients to those from a 
healthy donor. Strikingly, the amounts of p52 compared with p100 were greater in both NEMO-
mutant PBMC samples (Q403X and C417R) compared with control donor cells or LIGHT-
activated human umbilical vein endothelial cells (HUVEC) (Madge, Kluger et al. 2008) (Fig. 37).  
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Figure 36. Constitutive classical NF-κB transcription rescues low basal NIK. (A) NEMOKO 
MEFs stably transduced with either MigR1 or MigR1 encoding WT IKKβ were transfected with the 
pBIIx-κB firefly luciferase (FFL) and the TK renilla luciferase (RL) vectors. Twenty-four hours 
later, classical NF-κB transcriptional activity was determined as the fluorescence ratio of FFL:RL. 
(RLU, Relative Luciferase Units). Data are means ± SEM of six replicates from two independent 
experiments. **P < 0.01 by student’s two-tailed t-test. (B) WT or NEMOKO MEFs stably 
transduced with either MigR1 or MigR1 encoding WT IKKβ were analyzed by Western blotting 
with antibodies against the indicated proteins. Western blots are representative of three 
independent experiments. 
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Figure 37. The extent of p100 processing is enhanced in NEMO-ID cells. Lysates of PBMCs 
from patients with distinct NEMO mutations (Q403X and C417R), PBMCs from a healthy donor 
(Control), and HUVECs that were either untreated (-) or were stimulated with LIGHT for 8 hours 
(+) were analyzed by Western blotting with antibodies against the indicated proteins.  
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Notably, p100 was not detected in NEMOQ403X PBMCs, indicating that cellular p100 was 
completely processed to p52 in these cells (Fig. 37, lane 2). These data indicate that basal non-
canonical NF-κB signaling is hyperactive in NEMO-ID. 
Due to the scarcity of patient-derived material, we could not definitively determine the 
status of basal NIK in NEMO-mutant PBMCs. For this reason, we reconstituted NEMOKO MEFs 
with the hyper-IgA-associated Q403X and C417R mutants to further evaluate the effects of 
NEMO-ID mutations on non-canonical NF-κB signaling. Unlike the NEMO86-419 truncation mutant 
that cannot bind to IKKα or IKKβ, NEMOQ403X and NEMOC417R each associated with IKKα and 
IKKβ to form a heterotrimeric IKK complex in reconstituted cells (Fig. 38A).  Despite being able to 
form IKK complexes, neither NEMOQ403X nor NEMOC417R rescued TNF-induced NF-κB activation 
in NEMOKO MEFs, confirming that these mutations ablate stimulated classical IKK activity (Fig. 
38B).   
While proper NIK regulation was rescued in NEMOWT MEFs, elevated basal NIK was 
maintained in NEMOKO MEFs reconstituted with either NEMOQ403X or NEMOC417R (Fig. 39, lanes 
3, 7, and 9). We generated an additional NEMO-ID mutant MEF line harboring a mutation 
(NEMOL153R) in a distinct functional domain of the protein. This mutation did not permit classical 
NF-κB signaling in previous reports (Orange, Brodeur et al. 2002; Hanson, Monaco-Shawver et 
al. 2008), and importantly, NEMOL153R also failed to restore control of basal NIK levels (Fig. 39, 
lane 11). These findings establish that the ability of NEMO to form an IKK complex is insufficient 
to properly regulate the non-canonical NF-κB pathway; a signal-competent IKK complex and 
intact classical NF-κB activity are essential to maintain the quiescent state of the non-canonical 
NF-κB pathway. Furthermore, they suggest that aberrant non-canonical NF-κB activity may 
underlie the hyper IgA phenotype observed in patients with NEMO-ID.   
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Figure 38.  Mutant NEMO can form IKK complexes but not support classical NF-κB activity. 
(A) WT, NEMOKO, and NEMOKO MEFs retrovirally transduced with MigR1 or MigR1 encoding WT 
NEMO or the indicated NEMO mutants were lysed and then subjected to immunoprecipitation 
(IP) with anti-IKKα and anti-NEMO antibodies. Cell lysates and the immunoprecipitated samples 
were analyzed by Western blotting with antibodies against the indicated proteins. (B) WT and 
NEMOKO cells were transfected with the pBIIx-κB firefly luciferase (FFL) and the TK Renilla 
luciferase (RL) vectors. Twenty-four hours later, cells were either left untreated or were treated 
with TNF-α for 5 hours. NF-κB transcriptional activity was determined by measuring the 
fluorescence ratio of FFL:RL, and the extent of κB luciferase induction was defined as the fold-
difference between the TNF-α–stimulated samples and the controls. Data are means ± SD of four 
replicates in one of three independent experiments.  
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Figure 39. Elevated NIK in cells containing hypomorphic NEMO mutations. WT and 
NEMOKO MEFs retrovirally transduced with MigR1 or MigR1 encoding WT NEMO or the indicated 
NEMO mutants were either untreated (-) or incubated with anti-LTβR antibody for 8 hours (+) 
before being lysed and analyzed by Western blotting with antibodies against the indicated 
proteins. Western blots are representative of four independent experiments. 
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4.3. Discussion 
 In this chapter, we sought to understand the mechanism underlying aberrant NIK 
expression in cells that lack components of the classical IKK complex. Through co-
immunoprecipitation we have found that endogenous NEMO and NIK interact when NIK is 
stabilized by MG132 treatment. NEMO and NIK have previously been shown to interact when 
both proteins are over-expressed in 293 cells (Li, Kang et al. 1999). They have also been shown 
to interact directly in vitro (Li, Kang et al. 1999), however our results indicate that IKKα is required 
for the endogenous association of NEMO and NIK. Since we have been unable to detect 
association of NEMO with TRAF3 in the basal NIK regulatory complex, we hypothesized that the 
classical IKK complex might facilitate the IKKα-mediated turnover of active NIK.   
Unlike stable NIK present in IKKαKO MEFs, the NIK we detected in IKKβ-or NEMO-
deficient cells was phosphorylated, as it is in stimulated WT cells. Our experiments using CHX 
revealed that although NIK turnover in both resting and stimulated IKKαKO MEFs was defective, 
turnover occurred normally in cells lacking IKKβ or NEMO. We thus conclude that the classical 
IKK complex does not regulate IKKα-mediated NIK turnover but instead plays an obligate role in 
limiting the basal pool of newly synthesized NIK. Supporting this interpretation we found that the 
stable NIK in TRAF3KO MEFs (Liao, Zhang et al. 2004) is phosphorylated and turned over 
normally. Hence, basal NIK in cells lacking the intact classical IKK complex is identical to newly 
synthesized NIK that has escaped the TRAF2:TRAF3:cIAP1/2 basal regulatory machinery. These 
findings also confirm that TRAF3 plays no role in the IKKα-driven degradation of active NIK and 
imply that a novel regulatory mechanism is responsible for this phase of non-canonical pathway 
de-activation.   
IKKα (Razani, Zarnegar et al. 2010) and more recently, the IKK-like kinase TBK1 (Jin, 
Xiao et al. 2012) have been shown to phosphorylate NIK, leading to its controlled turnover. While 
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our results do not support a role for classical NF-κB signaling in negative feedback of the non-
canonical NF-κB pathway, NIK is clearly subject to multiple layers of regulation by IKK or IKK-like 
kinases. We have not directly ruled out a role for novel catalytic function by the heterotrimeric IKK 
complex, however our studies in p65KO MEFs reveal that ultimately, classical NF-κB activity is 
required to maintain undetectable NIK in resting cells. To accomplish this, classical NF-κB 
signaling may regulate a specific gene or gene panel that functions in basal NIK regulation. Likely 
candidate genes include TRAF2, TRAF3, the cIAPs or OTUD7B, a de-ubiquitinase that has been 
shown recently to regulate TRAF3 stability (Hu, Brittain et al. 2013). However we found that 
TRAF2, TRAF3, cIAP1, and cIAP2 protein amounts are similar or somewhat greater than WT 
MEFs among all of the cell lines we tested. Importantly, over-expressed NIK associates with 
endogenous TRAF3, TRAF2, and cIAP1 in WT MEFs or cells lacking NEMO or p65, suggesting 
that defective classical NF-κB signaling does not prevent the basal regulatory complex from 
forming in these cells.    
Mounting evidence has shown that cIAP1 and cIAP2 are functionally redundant in their 
role as E3 ubiquitin ligases regulating basal NIK; individual knockout cells must be complemented 
with siRNA or Smac mimetics to degrade the other cIAP and stabilize NIK (Vallabhapurapu, 
Matsuzawa et al. 2008; Zarnegar, Wang et al. 2008; Gardam, Turner et al. 2011). We observe 
similar levels of Birc3 transcription among p65KO and NEMOKO MEFs compared to WT MEFs, 
confirming the presence of this E3 ubiquitin ligase required for basal NIK regulation. Our data 
further suggest that the deubiquitinase OTUD7B (Hu, Brittain et al. 2013) is not involved in basal 
NIK regulation by the classical IKK complex, since TRAF3 stability is unaffected by the loss of 
NEMO or IKKβ. We therefore surmise that classical NF-κB signaling drives the expression of a 
unique gene or set of genes involved in non-canonical NF-κB regulation. Though the exact gene 
target remains to be determined, our results establish an obligate role for classical NF-κB activity 
to facilitate the quiescent state of non-canonical NF-κB in unstimulated cells (Fig. 40).  
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Figure 40. Classical NF-κB activity limits NIK protein amounts and constrains basal non-
canonical NF-κB activity. Classical NF-κB signaling mediated by p65 induces the expression of 
a novel gene target (X) required for the constraint of basal NIK amounts. This negative regulatory 
mechanism maintains the quiescent state of the non-canonical NF-κB activity. 
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Our findings reveal an essential role for the NEMO-dependent classical NF-κB pathway 
in negatively regulating basal non-canonical NF-κB activity. We show that naturally occurring 
NEMO-ID mutations prevent negative regulation of the non-canonical NF-κB pathway by the 
classical IKK complex in human disease. Patients with hypomorphic NEMO mutations exhibit a 
complex immunologic phenotype resulting in widespread immunodeficiency (Orange and Geha 
2003). The clinical presence of hyper-IgA in NEMO-ID is intriguing, as non-canonical NF-κB 
signaling has recently been shown to directly control class switch to the IgA isotype (Jin, Xiao et 
al. 2012). B cell-specific deletion of TBK1 in mice leads to NIK stabilization and nephritis due to 
prolonged non-canonical signaling and elevated IgA levels (Jin, Xiao et al. 2012). We found that 
unstimulated PBMCs from patients with NEMO mutations associated with hyper-IgA exhibit 
extremely high p100 processing, supporting a defect in basal regulation of non-canonical NF-κB. 
Thus we conclude that in a subset of NEMO-ID patients, defective classical NF-κB activation 
leads to elevated basal non-canonical NF-κB activity. This finding provides a mechanism for 
aberrant class switch in NEMO-ID and represents an in vivo human demonstration of the 
dysregulated non-canonical NF-κB signaling pathway.  
As limited sample availability precluded definitive determination of the status of NIK in 
NEMO-ID patient PBMCs, we established stable MEF lines expressing pathological NEMO 
mutations. In each case the NEMO-ID mutants assembled with endogenous IKKα and IKKβ to 
form a heterotrimeric IKK complex; however, consistent with previous studies these complexes 
were unable to activate classical NF-κB (Makris, Roberts et al. 2002; Cordier, Vinolo et al. 2008).  
Furthermore, high basal NIK was detected in the NEMO-mutant cells. Hence our data establish 
that functional mutations of NEMO that do not prevent IKK complex assembly alter the basal 
regulation of the non-canonical NF-κB pathway. We have only been able to assess this defect 
retrospectively in clinical samples, but our studies support future assessment of non-canonical 
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NF-κB signaling in NEMO-ID patients. Moreover, these accumulated findings prompt a re-
evaluation of the current view that the classical IKK complex plays no role in non-canonical NF-
κB regulation.  
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CHAPTER 5. THE TURNOVER OF ACTIVE NIK IS PROTEASOME-DEPENDENT BUT DOES 
NOT REQUIRE CIAP1/2 
Data from this chapter have been submitted for publication with the following authors: Gray CM, 
McCorkell KA, Chunduru SK, McKinlay MA, and May MJ.   
5.1. Introduction 
Our studies exploring the functional relevance of the IKKα:NEMO association in non-
canonical NF-κB activity led us to discover a novel interplay between the classical and non-
canonical NF-κB signaling pathways required to constrain basal NIK amounts (Chapters 3 and 4). 
In addition to these mechanisms required to maintain the latent phase of non-canonical NF-κB 
signaling in resting cells, the duration of non-canonical activity is controlled by a crucial negative 
regulatory mechanism in which activated IKKα feeds back to phosphorylate NIK at specific C-
terminal serine residues (Razani, Zarnegar et al. 2010). These modifications promote NIK 
turnover to terminate non-canonical signaling; however, the precise mechanism of IKKα-induced 
NIK degradation remains unknown. In this chapter, we investigate the mechanism of active NIK 
turnover. As basal NIK is constitutively degraded via the proteasome, we hypothesize that active 
NIK turnover is also proteasome-dependent.  
Over-expression and inhibitor studies suggest that the TRAF2:TRAF3:cIAP1/2 complex 
that controls the basal turnover of newly synthesized NIK does not require prior NIK 
phosphorylation (Razani, Zarnegar et al. 2010). Importantly however, these experiments did not 
directly address a potentially distinct role for the cIAP1/2 in specifically controlling the turnover of 
activated endogenous NIK. As the cIAPs are to date, the only known regulators of basal NIK 
stability, we further hypothesized that cIAP1 and cIAP2 were required for the negative turnover of 
signal-induced NIK.  
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 5.2. Results 
5.2.1. Active NIK turnover occurs via the proteasome 
We employed the proteasome inhibitor MG132 to determine whether the proteasome  
plays a role in the IKKα-dependent turnover of endogenous signal-induced active NIK. Consistent 
with previous reports (Matsushima, Kaisho et al. 2001; Liao, Zhang et al. 2004; Qing, Qu et al. 
2005; Vallabhapurapu, Matsuzawa et al. 2008; Zarnegar, Wang et al. 2008; Sanjo, Zajonc et al. 
2010), pharmacological blockade of the proteasome using MG132 led to the accumulation of NIK 
in resting cells (Fig. 41A, lane 2), which confirms that basal NIK is constitutively degraded through 
the proteasome. However, analysis proteasome inhibition on the fate of signal-induced NIK is 
complicated by concomitant effects on basal NIK levels (Fig. 41A). We therefore used a 
combination of proteasome and translation inhibition to isolate signal-induced NIK. Importantly, 
NIK was undetectable in resting cells co-treated with MG132 and CHX, confirming that in the 
absence of proteasome function, protein synthesis inhibition prevented NIK accumulation (Fig. 
41A). As this inhibitor combination allowed us to specifically ablate newly synthesized NIK, we 
employed this strategy to determine the effects of proteasome inhibition on LIGHT-induced active 
NIK turnover. As shown in Figure 41B, NIK accumulation was induced by incubation of MEFs for 
four hours with LIGHT, and further incubation for one hour in CHX led to the loss of detectable 
NIK (lane 3). Moreover, inhibition of the proteasome with concomitant CHX treatment completely 
inhibited LIGHT-induced NIK turnover (compare lanes 3 and 4), indicating that active NIK is 
degraded in a proteasome-dependent manner. Notably, inhibition of the proteasome in the 
absence of CHX led to increased accumulation of NIK in LIGHT-stimulated cells (Fig. 41B, lane 
6), further indicating that CHX treatment isolated active NIK from the constitutively translated 
basal protein.   
Although MG132 is the most widely used proteasome inhibitor, it has been reported to 
have off-target effects on cathepsins and calpains in vitro (Kisselev, van der Linden et al. 2012). 
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Figure 41. Turnover of endogenous NIK is proteasome-dependent. (A) WT MEFs were 
treated with 10µM MG132 (+), MG132 plus 2.5 mg/ml cycloheximide (C), or MG132 plus vehicle 
control (V) for one hour. Whole cell lysates were immunoblotted with antibodies against the 
indicated proteins. (B) WT MEFs were treated with LIGHT for four hours followed by one hour of 
cycloheximide (C) or vehicle (V) one hour of cycloheximide plus MG132 (+) to inhibit the 
proteasome. Lysates were immunoblotted as in (A).  
A B 
!
"
! V
" "!
C
MG132 
NIK 
Tubulin 
1 2 3 4
!# !# C 
!# !# !#
C V V 
MG132 !#"# "#
NIK 
Tubulin 
1 2 3 4 5 6 
LIGHT 
  
 
87 
 
Therefore we also utilized the more selective inhibitor bortezomib (Velcade, PS-341) (Adams, 
Palombella et al. 1999; Goldberg 2012) to confirm the role of the proteasome in active NIK 
turnover. Similar to MG132, bortezomib inhibits the chymotrypsin-like enzymatic site of the 20S 
core particle of the 26S proteasome (Goldberg 2012) and, as expected, both inhibitors blocked 
TNF-induced proteasome-dependent degradation of IκBα in the classical NF-κB signaling 
pathway (Hayden and Ghosh 2008) (Fig. 42A). As above (Fig. 41B), LIGHT treatment promoted 
NIK stabilization and subsequent incubation with CHX led to the loss of LIGHT-induced activated 
NIK (Fig. 42B). Importantly, NIK turnover during CHX incubation was blocked by pretreatment 
with either MG132 or bortezomib (Fig. 42B). These data establish, with two different 
pharmacological inhibitors, that the rapid IKKα-dependent turnover of endogenous NIK occurs in 
a proteasome-dependent manner. 
5.2.2. Turnover of active NIK is independent of cIAP1 and cIAP2 
 The sensitivity of NIK turnover to proteasome inhibition suggests that active NIK is 
ubiquitylated, thereby targeting it for degradation. As cIAP1 and cIAP2 are currently the only E3 
ubiquitin ligases implicated in basal NIK degradation (Vallabhapurapu, Matsuzawa et al. 2008; 
Zarnegar, Wang et al. 2008), we hypothesized that in addition to controlling the degradation of 
newly synthesized NIK, cIAP1/2 also ubiquitylated active, phosphorylated NIK. To assess the 
requirement of cIAP1/2 in NIK turnover, we used a Second mitochondria-derived activator of 
caspase (Smac or DIABLO) mimetic to degrade endogenous cIAP1/2 (Varfolomeev, Blankenship 
et al. 2007). Smac is a mitochondrial protein that is released upon induction of apoptosis. In the 
cytoplasm, Smac associates with and inhibits IAP proteins, thus permitting caspase activation 
and apoptosis (Gyrd-Hansen and Meier 2010). Because Smac potently induces apoptotic 
signaling, small molecule IAP antagonists mimicking the N-terminal tetrapeptide IAP binding motif 
(IBM) of Smac have been developed as anti-cancer therapeutics (Chen and Huerta 2009). These 
Smac mimetics bind to IAPs and promote their auto-ubiquitylation and proteasomal degradation 
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Figure 42. Two different proteasome inhibitors block active NIK degradation in MEFs. (A) 
WT MEFs were either left untreated or incubated with 500 nM MG132 or 500 nM bortezomib for 8 
hours. Cells were then stimulated with TNF for 15 minutes. Lysates were immunoblotted with 
antibodies against the indicated proteins. (B) WT MEFs were treated with 500 nM MG132 or 500 
nM bortezomib, with (+) or without (-) LIGHT for 6.5 hours. Cells were subsequently incubated 
with cycloheximide (C) or vehicle control (V) for 90 minutes. Whole cell lysates were 
immunblotted as in (A).  
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(Gyrd-Hansen and Meier 2010). We therefore obtained a novel Smac mimetic, GT13072, to 
specifically ablate cIAP1/2 and assess their requirement in active NIK turnover. 
In resting MEFs, GT13072 treatment led to rapid loss of cIAP1 and induction of NIK, 
whereas an inactive version of the compound (GT13199) did not (Fig. 43A). Notably, treatment 
with GT13072 induced NIK stabilization and p100 processing more rapidly than LIGHT (Fig. 43B). 
Furthermore, GT13072 treatment induced a second NIK band of greater apparent molecular 
weight in WT MEFs that was not detected in GT13072-treated IKKαKO MEFs (Fig. 43C). 
Together, these results suggest that release of NIK from the TRAF2/3:cIAP1/2 complex promotes 
its phosphorylation by IKKα in a manner similar to that induced by the natural ligand LIGHT or a 
cross-linking antibody against the LTβR (Fig. 43C, lane 11). We therefore used GT13072 to 
determine if cIAPs are further required to promote the turnover of NIK once it has been released 
from the TRAF2/3:cIAP1/2 complex. To specifically isolate GT13072-induced NIK from basally 
translated NIK, we employed the CHX chase assay established in Figure 9. Similar to LIGHT-
induced NIK, NIK stabilized by pre-treatment with GT13072 was turned over within sixty minutes 
of CHX treatment, despite the absence of cIAP1 (Fig. 44). These experiments show that cIAP1 is 
dispensable for the turnover of active NIK in MEFs.   
Although we were unable to detect resting cIAP2 protein in MEFs, NIK was stabilized by 
GT13072 treatment alone (Fig. 43A). As cIAP1 and cIAP2 have been shown to be functionally 
redundant in basal NIK regulation (Zarnegar, Wang et al. 2008), this suggested that GT13072 
also degraded any endogenous cIAP2. However, to ensure that cIAP1 and cIAP2 did not play 
distinct roles in the turnover of active NIK, we assessed NIK regulation in HeLa cells, which 
express cIAP1 and cIAP2 (Fig. 45A). GT13072 treatment led to the rapid loss of both cIAP1 and 
cIAP2 in HeLa cells followed by NIK stabilization (Fig. 45A). As in MEFs, treatment with GT13072 
induced p100 processing similar to the natural ligand LIGHT (Fig. 45B). Importantly, CHX chase  
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Figure 43. The Smac mimetic GT13072 stabilizes NIK. (A) WT MEFs were treated for four 
hours with either 1 µM smac mimetic GT13072 or the inactive compound GT13199. Cells were 
lysed and immunoblotted with antibodies against the indicated proteins. (B) WT MEFs were 
treated with LIGHT or GT13072 for up to twelve hours. Lysates were immunoblotted with 
antibodies against the indicated proteins. (C) WT (top) or IKKαKO (bottom) MEFs were treated 
with GT13072, GT13199, or anti-LTβR Ab for up to 24 hours. Whole cell extracts were 
immunblotted for NIK, cIAP1, and tubulin.  
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Figure 44. cIAP1 is not required for endogenous NIK turnover in MEFs. WT MEFs were 
stimulated with either LIGHT (top) or GT13072 (bottom) for four hours to stabilize NIK. Cells were 
then treated with 2.5 µg/ml cycloheximide (CHX) or vehicle control (V) for up to one hour. Cells 
were lysed and immunoblotted for the indicated proteins.  
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Figure 45. The Smac mimetic GT13072 stabilizes NIK in HeLa cells. (A) HeLa were treated 
for four hours with either 1 µM smac mimetic GT13072 or the inactive compound GT13199. Cells 
were lysed and immunoblotted with antibodies against the indicated proteins. (B) HeLa cells were 
treated with LIGHT or GT13072 for up to twelve hours. Lysates were immunoblotted with 
antibodies against the indicated proteins.  
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experiments that allow active NIK to be distinguished from the basally translated protein revealed 
that negative regulation of NIK was intact in HeLa cells after GT13072-induced cIAP1/2 
degradation (Fig. 46). These results thereby establish that endogenous cIAP1 and cIAP2 are 
dispensable for the turnover of active NIK.    
5.2.3. NIK turnover in the absence of cIAP1/2 occurs through the proteasome  
Thus far we have established that active NIK turnover induced by LIGHT requires the 
proteasome. Moreover, turnover of GT13072-stabilized NIK occurs in the absence of cIAP1 and 
cIAP2 in both MEFs and HeLa cells. We therefore questioned whether GT13072-induced NIK 
turnover, like that stimulated by LIGHT, required the proteasome. To specifically follow the 
destabilization of active NIK induced by GT13072, we employed the co-treatment strategy 
described in Figure 41. Similar to the effects in MEFs (Fig. 41A), treatment of HeLa cells with 
MG132 stabilized basal NIK, a process that was dependent on new protein synthesis (Fig. 47). 
Therefore, we next activated NIK using GT13072 and assessed the effect of MG132 on NIK 
turnover following CHX treatment. Figure 48 shows that in both HeLa cells and MEFs, NIK 
turnover is blocked by co-incubation of MG132 with CHX (compare lanes 3 and 4). Thus we 
conclude that unlike basal NIK turnover, which absolutely requires cIAP1/2 (Vallabhapurapu, 
Matsuzawa et al. 2008; Zarnegar, Wang et al. 2008), proteasome-dependent turnover of active 
endogenous NIK does not require the cIAPs. Together, our data support a model in which the 
negative feedback control of IKKα-induced NIK turnover occurs via a novel proteasome-
dependent but cIAP-independent mechanism (Fig. 49).   
5.3. Discussion 
A growing body of evidence that the non-canonical NF-κB pathway plays a pathological 
role in disease underscores the importance of fully elucidating mechanisms of NIK regulation. 
Genetic alterations in the basal regulatory complex have been associated with multiple myeloma 
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Figure 46. cIAP1/2 are not required for NIK turnover in HeLa cells. HeLa cells were 
stimulated with either LIGHT (left) or GT13072 (right) for four hours to stabilize NIK. Cells were 
then treated with 2.5 µg/ml cycloheximide (CHX) or vehicle (V) for up to one hour. Cells were 
lysed and immunoblotted with antibodies against the indicated proteins.   
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Figure 47. Concomitant translation and proteasome inhibition prevents NIK accumulation. 
HeLa cells were treated with 10 µM MG132 (+), MG132 plus 2.5 µg/ml cycloheximide (C), or 
MG132 plus vehicle control (V) for one hour. Whole cell lysates were immunoblotted with 
antibodies against the indicated proteins. 
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Figure 48. MG132 blocks NIK turnover in the absence of cIAP1/2. (A and B) WT MEFs (A) or 
Hela cells (B) were treated with GT13072 for four hours to stabilize NIK. Cells were then 
stimulated with 2.5 µg/ml cycloheximide (C) or cycloheximide plus 10 µM MG132 (+) for one 
hour. (V, vehicle control). Whole cell extracts were immunoblotted with antibodies against the 
indicated proteins.  
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Figure 49. Model for IKKα-mediated NIK turnover. Upon receptor ligation, stabilized NIK 
(purple oval) activates the non-canonical NF-κB pathway. Once active, IKKα phosphorylates NIK 
(P), leading to its degradation via the proteasome (gray cylinder), which does not require cIAP1/2.  
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and melanoma in humans. (Annunziata, Davis et al. 2007; Keats, Fonseca et al. 2007; Dhawan, 
Su et al. 2008; Thu and Richmond 2010). More recently, blocking either the E3 ubiquitin ligase 
activity of cIAP2 or the negative turnover of active NIK have been shown to result in B cell 
hyperplasia and kidney nephropathy in mice (Conze, Zhao et al. 2010; Jin, Xiao et al. 2012). As 
regulatory mechanisms of non-canonical NF-κB signaling precisely control NIK stability, defining 
these mechanisms is crucial for the development of novel therapeutic strategies aimed at 
selectively manipulating this pathway.   
IKKα-mediated negative feedback control of non-canonical NF-κB signaling requires the 
phosphorylation of NIK (Razani, Zarnegar et al. 2010). Here we show in both MEFs and HeLa 
cells that this post-translational modification directs the active kinase to the proteasome for 
degradation. The most common mechanism of signal-induced proteasomal targeting is 
ubiquitylation (Pickart 1997; Finley 2009), and previous overexpression studies have shown that 
NIK can be ubiquitylated by exogenous cIAP1 or cIAP2 (Vallabhapurapu, Matsuzawa et al. 2008; 
Zarnegar, Wang et al. 2008; Razani, Zarnegar et al. 2010). Yet these experiments did not 
distinguish between ubiquitylation of basally translated NIK and NIK stabilized by activating 
ligands.   
 We have previously shown that TRAF3 is dispensable for active NIK turnover (Gray, 
Remouchamps et al. 2014). However, since cIAP1/2 are the only E3 ubiquitin ligases known to 
target NIK directly, we hypothesized that cIAP1/2 might play a TRAF3-independent role in the 
turnover of active NIK. Our results using the Smac mimetic GT13072 show that loss of cIAP1/2 
has no effect on the turnover of active NIK. Thus we conclude that ubiquitylation of NIK by cIAP1 
and cIAP2 is limited to only the newly synthesized protein controlled by the basal TRAF3:TRAF2 
regulatory complex. Our data therefore suggest that phosphorylated NIK is ubiquitylated by a  
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currently unidentified E3 ubiquitin ligase that targets it for proteasomal degradation. One potential 
candidate is β-TrCP, which is required for the ubiquitylation of IκBs in the classical NF-κB 
pathway (Hayden and Ghosh 2008).  Active NIK is phosphorylated by IKKα on three distinct 
serines (Ser809, Ser812, and Ser815) (Razani, Zarnegar et al. 2010) that resemble the β-TrCP 
consensus sequence (DSGXXS) (Hayden and Ghosh 2008). Whether β-TrCP or another E3 
ubiquitin ligase controls induced NIK turnover will be an important area of future research to 
selectively manipulate the duration of non-canonical NF-κB activity.  
As we have ruled out the cIAPs as E3 ubiquitin ligases targeting NIK, an alternative 
possibility exists whereby active NIK is phosphorylated by IKKα and degraded by the 20S 
proteasome via a ubiquitin-independent mechanism. While such a mechanism is rare, several 
proteins including p53 and Ornithine Decarboxylase (ODC) can be degraded “by default” (Asher, 
Reuven et al. 2006; Finley 2009; Tsvetkov, Reuven et al. 2010). Our results cannot conclusively 
eliminate this possibility and ubiquitin-independent degradation of active NIK is an intriguing 
mechanism to consider. 
Collectively our findings separate the molecular requirements for active NIK turnover from 
those involved in the basal regulation of newly translated protein, thus revealing a previously 
unappreciated layer of NIK regulation. Increasing reports of dysregulated non-canonical NF-κB 
signaling in disease (Thu and Richmond 2010; Razani, Reichardt et al. 2011; Sun 2011) and the 
critical role of NIK stabilization in non-canonical signaling (Sun 2010) underscore the importance 
of fully elucidating the mechanism of active NIK turnover to develop novel therapeutic strategies 
to terminate the non-canonical NF-κB signaling pathway.   
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CHAPTER 6. CONCLUSIONS AND IMPLICATIONS 
6.1. Progress and outstanding questions 
In this thesis, we set out to investigate regulatory mechanisms of non-canonical NF-κB 
signaling. We have contributed to the current understanding of non-canonical NF-κB signal 
transduction with three major findings: IKKα, independent of its association with NEMO, is 
sufficient to activate the non-canonical signaling pathway and feed back to promote the negative 
turnover of active NIK (Chapter 3); Homeostatic classical NF-κB activity is required to suppress 
basal NIK amounts and maintain the quiescent state of the non-canonical pathway in resting cells 
(Chapter 4); Active NIK turnover is proteasome-dependent but does not require cIAP1/2 (Chapter 
5). These findings advance our understanding of a newly described mechanism of negative 
feedback regulation on non-canonical NF-κB activity and importantly, prompt reevaluation of the 
current paradigm, which indicates that NEMO plays no role in non-canonical NF-κB signaling.  
While these results increase our knowledge of non-canonical NF-κB biology, they also 
raise important questions that will be discussed in detail below. For example, IKKα does not need 
to associate with NEMO to promote non-canonical signaling, however IKKα does have a 
functional NBD. Therefore it may be activated by NIK as part of the heterotrimeric IKK complex; 
alternatively, the possibility remains that IKKα exists as a cytoplasmic homodimer to promote 
non-canonical NF-κB signaling. Furthermore, we show that NEMO and NIK associate in an IKKα-
dependent manner but the functional relevance of this remains unclear.  
A major finding from this thesis work is that homeostatic classical NF-κB activity is 
required to negatively regulate basal NIK, however we do not know what gene(s) are driven by 
classical NF-κB to suppress NIK. In that regard, it will be important to understand how this gene 
or genes control basal NIK. We also correlate hyperactive non-canonical NF-κB signaling due to 
loss of classical NF-κB activity with hyper-IgA in NEMO-ID, but it remains to be determined 
  
 
101 
whether dysregulated cross talk between NF-κB signaling pathways drives class switch to IgA in 
NEMO-ID patients.   
In seeking to understand the mechanism of active NIK turnover, we show that 
phosphorylated NIK is degraded via the proteasome in a cIAP-independent manner. It will be 
important to elucidate whether active NIK is directed to the proteasome by ubiquitylation; if so, 
what E3 ubiquitin ligase facilitates this process.  
Finally, our results suggest that an intact IKK complex is required to maintain the resting 
state of non-canonical NF-κB. Therefore, we reconsider use of the NBD peptide (NBDp) as an 
anti-inflammatory therapeutic in diseases where classical NF-κB signaling is targeted by this 
peptide. Additionally, we consider whether small molecular inhibitors of classical NF-κB remain 
an appropriate approach to cancer therapy. Ultimately, the elucidation of these answers will lead 
to exciting advances in our understanding of non-canonical NF-κB signal transduction. 
6.2. IKKα  homodimers may exist in vivo, but may not be functionally relevant for non-
canonical NF-κB activity 
We used a biochemical approach to show that the interaction between IKKα and NEMO 
is dispensable for induced p100 processing and NIK turnover. However, this complementation 
approach in IKKαKO MEFs does not determine whether IKKα exists independent of the 
heterotrimeric IKK complex to perform these functions in vivo. It is possible that cells contain a 
cytoplasmic pool of IKKα that, separate from NEMO and IKKβ, facilitates non-canonical NF-κB 
signaling. To begin to investigate whether cells contain a cytoplasmic pool of IKKα independent 
of the heterotrimeric IKK complex, we performed a series of NEMO immunodepletions in WT 
MEFs. We surmised that elimination of NEMO-bound IKKα would allow us to determine whether 
the proposed “IKKα-alone” complex remained in the immunodepleted samples. We 
immunoprecipitated NEMO from WT MEF whole cell extracts to deplete cells of the heterotrimeric 
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IKK complex. Subsequent rounds of IP completely eliminated detectable levels of NEMO and 
IKKβ (Fig. 50A).  Importantly, after three rounds of successive NEMO IP, samples still contained 
a detectable amount of IKKα (Fig. 50B, lane 4). This experiment indicates that WT MEFs do 
indeed contain a pool of IKKα that is independent of the heterotrimeric IKK complex; it must be 
repeated to see if this is a consistent result. While this finding in isolation does not determine 
whether IKKα-alone or NEMO-bound IKKα is activated by NIK, it still supports the genetic model 
that IKKα-alone does exist in whole cells.  
Alternatively, the cytoplasmic IKKα observed in this experiment may carry out the kinase-
independent function of IKKα described for keratinocyte differentiation (Hu, Baud et al. 2001) or 
the nuclear role of IKKα in Histone-H3 phosphorylation (Anest, Hanson et al. 2003; Yamamoto, 
Verma et al. 2003). Thus, while the association between NEMO and IKKα is not required for non-
canonical signaling, IKKα engaged in non-canonical signaling may be part of the heterotrimeric 
IKK complex. In support of this notion, we have found that NIK associates with NEMO via IKKα 
when NIK is stabilized with MG132 (Chapter 4). It will be important to investigate whether this 
interaction persists when cells are stimulated through the LTβR to activate the non-canonical NF-
κB pathway. If it does, this would suggest that IKKα involved in non-canonical signaling actually 
does bind NEMO in vivo, despite the association with NEMO not being absolutely necessary for 
non-canonical activation.  
6.3. Classical IKK activity constrains basal NIK  
While investigating the role of the IKKα:NEMO interaction by reconstitution of a C-
terminal truncation mutant of IKKα, we performed parallel experiments in NEMO-deficient cells 
(Chapter 3). These studies led to the surprising result that NEMO and catalytically competent 
IKKβ are required to suppress basal p100 processing. Interestingly, IKKα kinase activity and 
elevated p52 levels were both observed in resting NEMOKO MEFs in a seminal study that led to 
the discovery of the non-canonical NF-κB pathway (Dejardin, Droin et al. 2002). At that time the 
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Figure 50. A cytoplasmic pool of IKKα  exists independent of the heterotrimeric IKK 
complex. (A) WT MEFs were lysed and the heterotrimeric IKK complex was immunoprecipitated 
using anti-NEMO antibodies. Two subsequent rounds of immunodepletion were performed on the 
same samples. (B) Whole cell lysates prior to immunodepletion (pre-IP) and lysates following 
each round of IP (post-) were immunoblotted using the indicated antibodies. 
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authors suggested that these results were due to inherent IKKα activity that is constrained when 
the kinase associates with NEMO (May, D'Acquisto et al. 2000; Dejardin, Droin et al. 2002). 
However, we show that IKKα is basally active in IKKβ-deficient MEFs, and we have previously 
shown that NEMO:IKKα complexes exist in these cells (Solt, Madge et al. 2007). Therefore, loss 
of the NEMO:IKKα association does not fully explain the basal IKKα catalytic activity in NEMOKO 
cells. Moreover, we show that NEMO- and IKKβ-deficient MEFs have elevated NIK amounts prior 
to stimulation, which could explain how IKKα becomes activated in these cells. Finally, 
reconstitution of IKKβKO MEFs with a WT version of IKKβ reduces basal NIK amounts and IKKα 
activity. Together these results lead us to conclude the classical IKK complex is required to 
constrain non-canonical NF-κB activity via NIK regulation, which challenges the current model of 
NEMO-independent non-canonical NF-κB signaling.     
 We have shown that NEMO and IKKβ must associate to regulate non-canonical NF-κB 
signaling. Furthermore, the IKK complex must be catalytically competent for this function, as 
basal NIK is not properly constrained in cells that express a kinase dead mutant of IKKβ or have 
hypomorphic NEMO mutations that preclude classical NF-κB activity. Our finding that NEMO 
associates with NIK suggests that IKKβ may phosphorylate NIK directly to promote basal NIK 
turnover. We cannot rule out this mechanism based on the studies presented here, and it will be 
interesting to ascertain whether IKKβ, like IKKα (Razani, Zarnegar et al. 2010), has any kinase 
activity towards NIK in vitro. However, the similar phenotype of elevated basal NIK in cells that 
lack the prototypic NF-κB protein p65 led us to pursue the alternative hypothesis that classical 
NF-κB transcriptional activity was required for basal NIK regulation.  
6.4. Homeostatic NF-κB activity drives the expression of a novel factor required for basal 
NIK degradation 
Due to its prominent role in activation-induced gene expression, NF-κB is considered a 
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family of inducible transcription factors (Hayden and Ghosh 2008). Despite our minimal 
mechanistic understanding, the concept of basal NF-κB activity is not new (Baltimore 2011). For 
example, resting cells in the latent phase of signaling exhibit basal NF-κB activity measured by 
EMSA (Claudio, Brown et al. 2002; Notarangelo, Lanzi et al. 2006). Similarly, a cold competitor 
probe decreases basal κB binding in WT MEFs (Dejardin, Droin et al. 2002). Moreover, a 
decrease in homeostatic NF-κB activity is observed in cell lines when individual IKK subunits are 
deleted (Hu, Baud et al. 1999; Li, Chu et al. 1999; Tanaka, Fuentes et al. 1999). The gene targets 
of this homeostatic signaling have yet to be defined, however the important interplay we describe 
here between the classical and non-canonical pathways highlights the importance of investigating 
this basal NF-κB activity. 
In accordance with the hypothesis that NIK is constrained by classical NF-κB-driven 
transcription, we found that enforced classical NF-κB activity by the over-expression of WT IKKβ 
in NEMO-deficient cells restored basal NIK amounts. We thus considered that classical NF-κB 
might drive the expression of genes encoding the proteins required for basal NIK degradation. 
However, cIAP1/2, TRAF2, and TRAF3 protein amounts were similar in all of the cell lines we 
tested. Furthermore, exogenously expressed NIK was able to associate with these proteins in 
NEMO- and p65-deficient MEFs. These results suggest that classical NF-κB transcriptional 
activity is not required for the interaction of NIK with the previously described basal degradation 
complex. It remains possible that classical NF-κB is required for the transcription of genes whose 
products are required to promote NIK ubiquitylation by this complex. We favor this possibility 
because diverse genetic mutations affecting components of this complex lead to NIK stabilization 
and multiple myeloma in humans (Annunziata, Davis et al. 2007; Keats, Fonseca et al. 2007). 
Furthermore, the studies that first described the TRAF2:TRAF3:cIAP1/2 basal regulatory complex 
used over-expression and complementation of knockout MEFs to show that the coordinated 
efforts of these proteins promoted NIK ubiquitylation and degradation (Varfolomeev, Blankenship 
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et al. 2007; Vallabhapurapu, Matsuzawa et al. 2008; Zarnegar, Wang et al. 2008). Thus an 
endogenous NF-κB-dependent factor required to activate the ubiquitin ligase complex may not 
have been obvious in this system.  
A growing body of literature suggests that basal NIK degradation facilitated by the 
TRAF2:TRAF3:cIAP1/2 complex may be regulated by additional factors (Lavorgna, De Filippi et 
al. 2009; Hupalowska, Pyrzynska et al. 2012; Choudhary, Kalita et al. 2013; Yamaguchi, Oyama 
et al. 2013). TRAF1 has been proposed to positively regulate non-canonical NF-κB activity in B 
(Lavorgna, De Filippi et al. 2009) and T (Choudhary, Kalita et al. 2013) lymphocytes. In B cells, 
TRAF1 may interact with BAFF-R, promoting TRAF3 degradation and NIK stabilization, though 
the physiologic source of TRAF1 is unknown (Lavorgna, De Filippi et al. 2009). In T cells, TRAF1 
is induced by CD3 signaling. In this model, TRAF1 associates with NIK, displacing it from the 
TRAF2:TRAF3:cIAP1/2 complex and thus relieving the negative regulation on basal NIK protein 
(Choudhary, Kalita et al. 2013). Additionally, the anti-apoptotic protein A20 has been shown to 
positively regulate non-canonical signaling, as LTβR, Fn14, or RANK signaling do not induce NIK 
accumulation in A20-deficient MEFs (Yamaguchi, Oyama et al. 2013). In WT MEFs, LTβR 
engagement induces A20 concomitant with NIK expression. Exogenously expressed A20 
associates directly with cIAP1, blocking its interaction with TRAF2 and inhibiting the function of 
the TRAF2:TRAF3:cIAP complex (Yamaguchi, Oyama et al. 2013). Disruption of the basal 
degradation complex by A20 permits NIK stabilization and has been described as a “molecular 
switch” between classical and non-canonical NF-κB activity downstream of the LTβR 
(Yamaguchi, Oyama et al. 2013). Finally, Adaptor Protein Containing Pleckstrin Homology 
Domain, Phosphotyrosine Binding Domain, and Leucine Zipper Motif 1 (APPL1) has been shown 
to promote NIK stabilization by disruption of the basal regulatory complex (Hupalowska, 
Pyrzynska et al. 2012). Because each of these proteins positively influences non-canonical NF-
κB signaling, we do not anticipate TRAF1, A20, or APPL1 being the classical NF-κB gene target 
implicated in our studies. However, a negative regulator of any one of these factors may be 
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maintained by classical NF-κB transcription, the loss of which could prevent constitutive NIK 
turnover and promote non-canonical signaling in resting cells. Ultimately, these experiments 
illustrate that basal NIK regulation by TRAF2:TRAF3:cIAP1/2 may be more complex than 
originally described.  
6.5. Hyperactive non-canonical NF-κB may induce hyper IgA in NEMO-ID 
The presentation of hyper IgA in NEMO-ID is especially perplexing in light of the positive 
role for NEMO in class switch recombination (Notarangelo, Lanzi et al. 2006). Coupled with the 
recently reported role for NIK in class switch to the IgA isotype in the mouse model (Jin, Xiao et 
al. 2012), we investigated non-canonical NF-κB signaling in NEMO-ID. We found that samples 
from patients with two distinct mutations in the C-terminal zinc finger of NEMO (Q403X and 
C417R) exhibited high ratios of p52:p100, indicative of basal p100 processing and non-canonical 
NF-κB activity. Furthermore, NEMOQ403X and NEMOC417R MEFs have elevated basal NIK 
compared to NEMOWT controls. Our findings correlate classical NF-κB signaling defects with 
dysregulated NIK and hyper IgA in NEMO-ID, and we think it will be important to monitor NIK 
expression and non-canonical NF-κB signaling in future clinical cases of this disease. However, it 
remains to be proven that hyper IgA is directly driven by elevated NIK due to decreased classical 
NF-κB activity. To test this, we would assess class switch recombination (CSR) in B cells from 
mice that have a loxP-flanked Ikbkb gene. Ex vivo deletion of IKKβ in mature splenic B cells using 
the Tat-Cre recombinase would permit us to test whether loss of IKKβ induces NIK accumulation 
and p100 processing. Importantly, we would perform CSR assays to see if these cells 
preferentially switch to the IgA isotype, further implicating aberrant NIK expression in this 
process. If IgA switching was not preferred in IKKβ-deficient cells crossed onto a NIK-deficient 
background, we would conclude that aberrant NIK expression, due to disrupted classical NF-κB 
activity, drives hyper IgA.  
  
 
108 
6.6. Hypomorphic NEMO mutations may reveal novel factors required for basal NIK 
regulation 
While we describe dysregulated NIK and basal p100 processing associated with three 
NEMO-ID mutations, Hyper IgA is not a ubiquitious clinical finding in NEMO-ID. In a database of 
45 patients with common hypomorphic NEMO mutations, 30% (6/20) were reported to have 
Hyper IgA, whereas approximately 12% of patients (2/17) reportedly had hyper IgM (Hanson, 
Monaco-Shawver et al. 2008). The latter finding is consistent with a role for NF-κB signaling in 
CSR downstream of CD40 (Notarangelo, Lanzi et al. 2006). Interestingly, classical NF-κB 
signaling is critical for B cell development and maintenance (Pasparakis, Schmidt-Supprian et al. 
2002; Claudio, Brown et al. 2006), however B lymphocyte numbers were normal in most patients 
with hypomorphic NEMO mutations (Hanson, Monaco-Shawver et al. 2008). Therefore it is clear 
that these particular NEMO mutants can transmit some classical NF-κB signals to support B cell 
development.  
As NEMO-ID is a heterogeneous disease with various defects leading to 
immunodeficiency, it is possible that certain mutations permit particular classical NF-κB signals 
required for basal NIK regulation that are disrupted in other hyper IgA-associated NEMO 
mutations like Q403X and C417R. Accordingly, it would be intriguing to assess non-canonical NF-
κB signaling in a cell with a hypomorphic NEMO mutation that has not been associated with 
hyper IgA. We would like to analyze different mutations in the zinc finger of NEMO because we, 
and others (Makris, Roberts et al. 2002), have shown that mutations in this domain prevent 
classical NF-κB signaling but not IKK complex formation. There are competing reports as to 
whether nonsense mutations at E391X result in Hyper IgM (Orange, Jain et al. 2004) or Hyper 
IgA (Hanson, Monaco-Shawver et al. 2008). However, 6/6 patients with frameshifts at the 
adjacent residue E390 (E390fs) reportedly had hypogammaglobulenemia and Hyper IgM with no 
Hyper IgA (Hanson, Monaco-Shawver et al. 2008). Additionally, the R319Q mutation is 
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associated with classical NF-κB defects but normal IgA serum levels. We hypothesize that non-
canonical NF-κB signaling would be properly regulated in NEMOKO MEFs reconstituted with 
E390fs or R319Q mutant NEMO. If basal NIK amounts were low and p100 was unprocessed in 
resting NEMOE390fs or NEMOR319Q cells, we would compare RNA expression profiles of WT and 
NEMO-deficient cells reconstituted with E390fs or R319Q versus Q403X or C417R 
(Nagalakshmi, Wang et al. 2008; Wilhelm, Marguerat et al. 2008). We anticipate that this analysis 
may reveal a novel gene product or products important for basal NIK regulation that are 
expressed at similar amounts in WT, NEMOE390fs and NEMOR319Q cells but are under-expressed 
in the NEMOQ403X and NEMOC417R cells. We believe this will be a more targeted approach to 
identifying the gene(s) required for basal NIK regulation than comparing WT and NEMOKO or 
p65KO MEFs, for example, because of the broad spectrum of genes controlled by classical NF-κB 
signaling. 
6.7. Does ubiquitin target active NIK for proteasomal degradation?  
 Similar to constitutive NIK degradation in a resting cell, we have shown that active NIK 
turnover occurs via the proteasome (Chapter 5). However, unlike the basal mechanism, cIAP1/2 
are dispensable for the IKKα-mediated turnover of active NIK. Thus we conclude that active, 
phosphorylated NIK is ubiquitylated by a different E3 ubiquitin ligase, which targets NIK for 
proteasomal degradation. In chapter 5 we suggested that the most likely candidate for this 
ubiquitin-dependent mechanism is β-TrCP. β-TrCP is the E3 ubiquitin ligase responsible for IκB 
ubiquitylation during the induction of NF-κB responses (Kanarek and Ben-Neriah 2012). 
Furthermore, the serine residues phosphorylated by IKKα (Razani, Zarnegar et al. 2010) 
resemble the β-TrCP recognition sequence (DSGXXS) (Kanarek and Ben-Neriah 2012). Future 
studies should be performed to assess active NIK turnover in the absence of β-TrCP.  
Our finding that the turnover of NIK absolutely requires the proteasome strongly suggests 
that active NIK is ubiquitylated. Despite intense efforts, we have been unable to detect 
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ubiquitylation of endogenous NIK under any conditions. However, we have preliminary evidence 
to suggest that exogenous NIK can be ubiquitylated under activating conditions, even in the 
absence of cIAP1/2 (Fig 51). While extensive work remains to establish that this experimental 
system definitively shows the ubiquitylation of active, exogenous NIK, we believe this may be a 
promising approach to answer this important remaining question. We aim to compare the 
ubiquitylation status of exogenous WT and mutant NIK 3SA, in which the serine residues 
phosphorylated by IKKα are mutated to alanines (Razani, Zarnegar et al. 2010) and therefore 
NIK 3SA is unable to be turned over. We surmise that the mutant NIK will only be ubiquitylated 
under basal conditions when the proteasome is inhibited and will not be ubiquitylated under 
activating conditions, whereas WT NIK will be ubiquitylated under both basal and activating 
conditions. Such a result would indicate that this experimental approach accurately assesses 
active NIK ubiquitylation downstream of IKKα-phosphorylation. Ultimately, we hypothesize that 
exogenous active WT NIK will be ubiquitylated in the absence of cIAP1/2, as our studies show 
that active NIK turnover via the proteasome is cIAP-independent (Fig. 49).  
While our preliminary data suggests that active NIK may be ubiquitylated prior to 
degradation, ubiquitin-independent proteasomal processing has been described. This type of 
degradation “by default” occurs via the 20S catalytic core component of the proteasome (Asher, 
Reuven et al. 2006). The 26S proteasome is comprised of the 20S core particle and two 19S 
regulatory caps, which bind to and unfold ubiquitylated proteins for regulated degradation via the 
26S proteasome (Kisselev, van der Linden et al. 2012). The most common proteasomal inhibitors 
MG132 and bortezomib block enzymatic activity of the 20S core particle. Thus they inhibit 
regulated proteasomal degradation as well as “default” protein turnover.  
We have shown that inhibition of the 20S core particle using MG132 and bortezomib 
prevents NIK turnover (Chapter 5). A new class of proteasome inhibitors blocks the ubiquitin   
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Figure 51. NIK may be ubiquitylated in the absence of cIAP1/2. HeLa cells were transfected 
with CMV-pFLAG WT NIK and either WT HA-Ub (+) or mutant HA-Ub (Ko). Twenty-four hours 
later, cells were stimulated with 10 µM MG132, with or without (-) either LIGHT (L) or GT13072 
(G) for 4 hours. Cells were subsequently incubated with CHX for 90 minutes and lysed. 
Exogenous NIK was immunoprecipitated (IP) with anti-FLAG (M2) beads, and proteins were 
immunoblotted with antibodies against HA and FLAG. Ten percent of the IP input (whole cell 
lysate, WCL) was run in parallel to indicate transfection efficiency. An HA-Ub band corresponding 
to the electrophoretic mobility of FLAG NIK is indicated by the asterisk (*). 
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binding function of the 19S cap protein (Kisselev, van der Linden et al. 2012). We have tested 
one such inhibitor to take an endogenous approach to determine whether proteasome-dependent 
active NIK turnover is regulated by ubiquitin, however the results are inconclusive and require 
further work. We hypothesize that a block in NIK turnover in the presence of the 19S cap inhibitor 
would indicate that active NIK degradation occurs via the 26S proteasome and is therefore 
facilitated by ubiquitin. Selectively targeting the 19S cap will be important to determine whether 
ubiquitin facilitates endogenous NIK turnover because we are currently limited to using 
exogenously expressed NIK in ubiquitylation assays. A more complete understanding of the 
molecular requirements for endogenous NIK turnover is necessary to determine whether this 
negative feedback mechanism is a potential therapeutic target for autoimmune diseases 
associated with accumulated NIK (Salomonsson, Larsson et al. 2002; Jin, Zhou et al. 2009). 
6.8. Implications for the NBDp as a classical NF-κB inhibitor  
IKKα and IKKβ associate with the N-terminal α-helix of NEMO via a six amino-acid 
sequence in their C-termini (LDWSWL) (May, D'Acquisto et al. 2000; May, Marienfeld et al. 
2002). Our lab has developed a cell-permeable peptide encompassing this NBD sequence, which 
disrupts the NEMO:IKK interaction (Fig. 52A) and prevents inducible classical NF-κB activation 
(May, D'Acquisto et al. 2000). The NBDp has been employed in many cellular and in vivo studies 
and is now well regarded as a potent and effective classical NF-κB inhibitor (Tas, Vervoordeldonk 
et al. 2006; Acharyya, Villalta et al. 2007; Gaurnier-Hausser, Patel et al. 2011). However, the 
effects of classical NF-κB inhibition via the NBDp on non-canonical NF-κB signaling have never 
been described. We now understand that classical NF-κB activity is required for basal regulation 
of the non-canonical NF-κB pathway, which prompts evalulation of non-canonical signaling after 
NBDp treatment. 
In preliminary studies we found that treatment with the NBDp alone led to p100 
processing in WT MEFs (Fig. 52B). NBDp-induced p100 processing was similar to that induced 
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by cross-linking the LTβR (Fig. 52B lane 8). NBDp efficiency was measured by its ability to block 
TNF-induced classical NF-κB activity (Fig. 52C), and classical NF-κB inhibiton by the NBDp was 
not complete in this experiment. Importantly, p100 was not processed to p52 when cells were 
treated with a mutant version of the NBDp that could not disrupt IKK activity (Fig. 52B lane 7, and 
Fig. 52C). NBDp treatment also induced p100 processing to p52 in HUVEC (M.J.M., unpublished 
observations), leading us to believe that disruption of the resting heterotrimeric IKK complex by 
NBDp administration may lead to NIK accumulation.  
While we observed p100 processing after NBDp treatment, we have been unable to 
observe NIK stabilization in NBDp-treated cells. Several possible explanations exist for this. First, 
the NBDp did not completely block classical NF-κB activity measured by EMSA (Fig. 52C). Thus, 
weakened classical activity may permit NIK stabilization such that IKKα becomes activated to 
phosphorylate p100, but NIK protein amounts remain below the level of detection by immunoblot. 
In fact, WT NBDp treatment alone was originally shown to enhance basal NF-κB activity two-fold 
(May, D'Acquisto et al. 2000). While this was interpreted as intrinsic kinase activity that is 
normally constrained by the association of IKKα and IKKβ with NEMO, it is interesting to imagine 
this increase in κB-driven luciferase activity was due to stabilization of NIK, as aberrant NIK 
expression has been shown to induce classical NF-κB activity (Malinin, Boldin et al. 1997; 
Ramakrishnan, Wang et al. 2004; Zarnegar, Yamazaki et al. 2008; Neely, Brose et al. 2010). This 
cross-talk between NIK and classical NF-κB is important to consider in potential cases of NBDp-
resistance. 
We can also envision a scenario whereby the NBDp blocks basal NF-κB activity such 
that NIK accumulates, but is rapidly degraded by IKKα-mediated negative feedback and thus NIK 
remains below the level of detection by immunoblot in this timecourse. Further experimentation is 
required to fully understand the effects of classical NF-κB inhibition by NBDp treatment on non-
canonical NF-κB activity. 
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Figure 52. The NEMO Binding Domain peptide (NBDp) induces p100 processing in MEFs. 
(A) Model showing how the NBDp (blue bars) disrupts the interaction of NEMO with IKKα/β. (B) 
WT MEFs were incubated with either the WT or mutant (Mut) NBDp, DMSO (vehicle) or anti-
LTβR for the times indicated.  Whole cell lysates were immunoblotted for p100 processing and 
tubulin was visualized as a loading control. (C) WT MEFs were either untreated (lanes 1 and 2) or 
pretreated with WT or mutant NBDp for two hours before stimulation with TNF for 30 minutes (+).  
Classical NF-κB activation was detected by EMSA using a specific κB probe and equal loading 
was determined using a probe bound by Oct-1. These data demonstrate that the WT NBD 
peptide used in panel (B) inhibited TNF-induced NF-κB activation. 
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While our preliminary results indicate the NBDp should be used with caution, this inhibitor 
has been proven to potently inhibit inducible classical NF-κB activity (May, D'Acquisto et al. 
2000). This makes it a desirable therapeutic for inflammatory diseases driven by excessive 
classical NF-κB signaling. Furthermore, because off-target effects of the peptide have not been 
reported, we do not forsee the interplay of classical and non-canonical NF-κB signaling hindering 
the utility of this approach in vivo. 
6.9. Classical NF-κB activity as a target for cancer therapy 
An important advance in cancer treatment has been the development of Smac mimetics. 
These cIAP antagonists have been developed as anti-cancer drugs because cIAPs are often 
overexpressed in human malignancies and protect cancer cells from normal inducers of cell 
death (Gyrd-Hansen and Meier 2010). Smac mimetics lead to cIAP auto-ubiquitylation and 
degradation, which in turn promotes caspase activation and induction of apoptotic signaling. cIAP 
antagonists also block NF-κB activity downstream of the TNFR; thus these small molecules have 
a two-pronged approach to cancer treatment by directly promoting cell death and inhibiting pro-
survival gene programs mediated by classical NF-κB (Gyrd-Hansen and Meier 2010). 
Accordingly, Smac mimetics have exquisite specificity for cancerous cells and transformed cell 
lines, with little effect on unmalignant primary cell cultures (Varfolomeev, Blankenship et al. 2007) 
(McCorkell et al. – manuscript in preparation). This is attributed to the apparent addiction of 
cancer cells to cIAP-dependent pro-survival signaling mediated by classical NF-κB. When cIAPs 
are ablated by Smac mimetics, autocrine TNF signaling promotes cell death, thus enhancing the 
effectiveness of this novel class of inhibitors.  
We and others (Varfolomeev, Blankenship et al. 2007) show a Smac mimetic also 
activates the non-canonical NF-κB pathway through loss of cIAP and stabilization of NIK. While 
loss of cIAP function will sensitize that particular cell to TNF-induced cell death, rapid non-
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canonical NF-κB activity after Smac mimetic treatment may lead to the induction of genes (ie., 
CXCL12, CXCL13, CCL19, and CCL21) whose products may promote lymphocyte recruitment to 
the tumor microenvironment. It will be important to discern whether this corollary activation of 
non-canonical NF-κB actually enhances treatment or causes certain tumors to be resistant to 
Smac mimetic therapy. 
Diffuse Large B cell Lymphoma (DLBCL) relies on classical NF-κB for the transcription of 
pro-proliferative (ie., CyclinD1) and anti-apoptotic genes (ie., Bcl-2, cFLIP, XIAP) (Feuerhake, 
Kutok et al. 2005; Lam, Davis et al. 2005; Davis, Ngo et al. 2010; Gaurnier-Hausser, Patel et al. 
2011). Therefore inhibitors of IKKβ have been developed to treat this lymphoid malignancy (Lam, 
Davis et al. 2005). The studies presented here spark concern for the efficacy of IKK inhibitors in 
lymphoma, as we find elevated basal NIK in cells that lack classical NF-κB activity. Moreover, 
constitutive BAFF-R signaling promotes NF-κB activity and B cell proliferation via NIK 
stabilization in DLBCL (Pham, Fu et al. 2011). Thus exacerbated non-canonical NF-κB activity 
due to IKKβ inhibition may promote BAFF-independent B cell survival and tumor persistence in 
this disease.  
6.10. Conclusion 
The overarching goal of these studies was to understand the molecular mechanisms 
regulating non-canonical NF-κB signal transduction. We demonstrate that classical NF-κB 
signaling limits the basal pool of NIK, identifying a novel function for the classical IKK complex 
and furthermore, classical NF-κB signaling in the negative regulation of the non-canonical NF-κB 
pathway. Thus the previous paradigm for two distinct NF-κB signaling pathways is incomplete 
and must be revised to include the contribution of classical NF-κB activity to basal NIK 
suppression in order to maintain the quiescent state of the non-canonical NF-κB pathway. Our 
studies also advance the current understanding of a negative feedback loop to control duration of 
non-canonical NF-κB signaling. We show that like basal NIK, active NIK is degraded via the 
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proteasome, but the molecular events facilitating this turnover are unique. The comprehensive 
signaling model described in this thesis (Fig. 53) will be especially critical to consider when 
developing inhibitors of classical NF-κB activity, as perturbation of this pathway promotes non-
canonical NF-κB signaling.  
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Figure 53. Comprehensive model for non-canonical NF-κB regulation. Under resting 
conditions (Basal), NIK (pale purple oval) is bound to TRAF2:TRAF3:cIAP1/2. This association 
facilitates the constitutive ubiquitylation and proteasomal degradation of NIK. However, the 
constraint of basal NIK protein amounts also requires p65-mediated classical NF-κB transcription. 
The exact gene target of classical NF-κB (Gene X) remains to be determined. Upon receptor 
ligation (Activated), NIK accumulates (dark purple oval) and activates IKKα, which in turn feeds 
back to phoshporylate (P) NIK. Phosphorylated NIK is degraded by the proteasome in a cIAP-
independent manner.  
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